US20120095007A2 - Carbamoyloxy arylalkan arylpiperazine analgesics - Google Patents

Carbamoyloxy arylalkan arylpiperazine analgesics Download PDF

Info

Publication number
US20120095007A2
US20120095007A2 US12/600,283 US60028308A US2012095007A2 US 20120095007 A2 US20120095007 A2 US 20120095007A2 US 60028308 A US60028308 A US 60028308A US 2012095007 A2 US2012095007 A2 US 2012095007A2
Authority
US
United States
Prior art keywords
phenyl
piperazin
carbamic acid
propyl ester
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/600,283
Other versions
US8815852B2 (en
US20100160331A1 (en
Inventor
Ki Ho Lee
Han Ju Yi
Hyeon Cho
Dae Joong Im
Eun Hee Chae
Yeon Jung Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Holdings Co Ltd filed Critical SK Holdings Co Ltd
Assigned to SK HOLDINGS CO., LTD. reassignment SK HOLDINGS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, YEON JUNG, CHAE, EUN HEE, CHO, HYEON, LEE, KI HO, YI, HAN JU
Publication of US20100160331A1 publication Critical patent/US20100160331A1/en
Assigned to SK HOLDINGS CO. LTD. reassignment SK HOLDINGS CO. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IM, DAE JOONG
Assigned to SK BIOPHARMACEUTICALS CO., LTD. reassignment SK BIOPHARMACEUTICALS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SK HOLDINGS CO., LTD.
Publication of US20120095007A2 publication Critical patent/US20120095007A2/en
Application granted granted Critical
Publication of US8815852B2 publication Critical patent/US8815852B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel carbamoyloxy arylalkan arylpiperazine compound, a pharmaceutical compositions comprising the compound and a method for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression in mammals by administering the compound to the mammals in need of treatment thereof.
  • arylpiperazine compounds were proven to be effective to a variety of indications in the field of central nervous system.
  • U.S. Pat. No. 3,002,976 reported that the following thiophene-engrafted arylpiperazine compound has a pharmacological effect to treat depression.
  • R represents hydrogen, methyl group or halogen.
  • R 1 is alkyl having carbon atoms of 1 to 6;
  • R 2 and R 3 are each independently alkyl having carbon atoms of 1 to 6, or R 2 and R 3 are taken together to form polymethylene having carbon atoms of 2 to 12 or to form a 5-norbornen-2-yl residue with carbon atoms bount to the radicals R 2 and R 3 ;
  • X is selected from the group consisting of —CO 2 —, —OCO—, —OCO 2 —, —N(R 7 )CO—, —NHNHCO—, —ON(R 7 )CO—, —CON(R 7 )—, —N(R 7 )CO 2 —, —OCON(R 7 )— and —N(R 7 )CON(R 8 )
  • R 7 and R 8 are each independently is selected from the group consisting of hydrogen; alkyl having carbon atoms of 1 to 6; phenyl; benzyl; and phenyl or
  • the present inventors have confirmed that an arylpiperazine structure is correlated with an effect to treat pains as well as anxiety and depression, conducted comprehensive researches on the arylpiperazine structure, and found that novel carbamoyloxy arylalkan arylpiperazine compounds have a medical effect in various pain-induced animal models.
  • the present inventors have found that the novel carbamoyloxy arylalkan arylpiperazine compounds show their therpeutic effects to treat a wide scope of pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression. Therefore, the present invention was completed on the basis of the above-mentioned facts.
  • An aspect of the present invention provides a novel carbamoyloxy arylalkan arylpiperazine derivative compound and pharmaceutically available salts or hydrates thereof.
  • Another aspect of the present invention provides a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound.
  • Still another aspect of the present invention provides a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.
  • a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
  • - - - may selectively form a cyclic ring
  • R 1 and R 2 are hydrogen, or R 1 or R 2 may be taken together with X 1 to form a bicyclic ring;
  • X 1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
  • Z is hydrogen or fluorine, or may be taken together with X 1 to form a bicyclic ring;
  • Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline;
  • Y 1 and Y 2 are each independently hydrogen or methyl (CH 3 );
  • Y 3 is hydrogen, phenyl, or carbonyl ( ⁇ O);
  • Y 4 is hydrogen, or methyl (CH 3 );
  • n is integer of 1 or 2;
  • n is integer of 0 or 1.
  • a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound having abundant racemic or enantiomeric characteristics.
  • a method for treating pain, anxiety or depression in mammals by administering to the mammals in need of treatment thereof an effective amount of the compound having abundant racemic or enantiomeric characteristics.
  • novel carbamoyloxy arylalkan arylpiperazine derivative compound, and salts and hydrates thereof according to the present invention may be effectively used as a therapeutic agent for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain and migraine headache, anxiety and depression.
  • the present invention is related to a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
  • - - - may selectively form a cyclic ring
  • R 1 and R 2 are hydrogen, or R 1 or R 2 may be taken together with X 1 to form a bicyclic ring;
  • X 1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
  • Z is hydrogen or fluorine, or may be taken together with X 1 to form a bicyclic ring;
  • Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline,
  • Y 1 and Y 2 are each independently hydrogen or methyl (CH 3 );
  • Y 3 is hydrogen, phenyl, or carbonyl ( ⁇ O);
  • Y 4 is hydrogen, or methyl (CH 3 );
  • n is integer of 1 or 2;
  • n is integer of 0 or 1.
  • the compounds according to one exemplary embodiment of the present invention may be chemically synthesized as in the following Schemes 1 to 3. However, they are described for the purpose of illustrations only, and the present invention is not particularly limited thereto.
  • HX represents acid that may form pharmaceutically available salts with a compound having basic nitrogen.
  • the acid includes, but is not particularly limited to, for example, hydrochloric aid, sulfuric aid, phosphoric acid, acetic acid, benzoic acid, citric acid, malonic acid, salicylic acid, malic acid, fumaric acid, oxalic acid, succinic acid, tartaric aid, lactic acid, gluconic acid, ascorbic acid, maleic acid, aspartic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxymethanesulfonic acid, hydroxyethanesulfonic acid, etc.
  • ether solvent tetrahydrofuran, ethylether, propylether, isopropylether, and butylether
  • alcohol solvent methanol, ethanol, and isopropyl alcohol
  • ester solvent ethyl acetate
  • halogenated hydrocarbon solvent dichloromethane, chloroform
  • a compound (1-3) was synthesized at the presence of a starting material (1-1) substituted by X 1 and phenylpiperazine (1-2) substituted by X 2 through a Mannich reaction.
  • a compound (1-4) was prepared by reducing the compound (1-3) with sodium borohydride (NaBH 4 ), reacted with 1,1-carbonyl dimidazole (CDI), and then reacted with various amines (NHR 1 R 2 ) to obtain a compound (1-5) and its salt (1-6).
  • reaction product (1-5) or its salt (1-6) prepared through the Scheme 1 was obtained in the form of a racemic compound.
  • CDI 1,1-carbonyl dimidazole
  • Stereochemistries of the reaction product (2-4) and its salt (2-5) depend only on the starting material (2-1); that is, the reaction product having an (S)-enantiomer only is obtained from the starting material (2-1) having an (S)-enantiomer, and the reaction product having a (R)-enantiomer only is obtained from the starting material (2-1) having a (R)-enantiomer.
  • a compound (3-3) was synthesized from phenyl-1-propenylketone (3-1) and substituents-engrafted phenylpiperazine (3-2) through 1,4-Michael addition.
  • the compound (3-3) was subject to the reduction reaction at the presence of sodium borohydride (NaBH 4 ) to obtain a compound (3-4) as an alcohol intermediate, and the compound (3-4) was reacted with 1,1-carbonyl dimidazole (CDI), as described previously above, to obtain a carbamate-engrafted compound (3-5) and its salt (3-6).
  • NaBH 4 sodium borohydride
  • CDI 1,1-carbonyl dimidazole
  • a pharmaceutical composition including an effective amount of the compound to treat pain, anxiety or depression.
  • the pharmaceutical composition includes, as an active component, at least one compound among the compounds as listed in this application, and the composition according to the present invention may include any combination of the compounds according to the present invention.
  • the pharmaceutical composition of present invention may be specifically formulated so that it can be administered via any form, such as suitable routes of administration.
  • suitable routes of administration may, for example, include oral, rectal, nasal, pulmonary, local, percutaneous, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and transdermal routes) routes.
  • the pharmaceutical composition of present invention is preferably administered via the oral route.
  • the preferred routes of administration will, of course, be varied depending on a variety of factors, including the general conditions and age of the subject being treated, the severity of the conditions being treated, and the selected active components, etc.
  • compositions formulated according to the present invention may be administered orally in any form of administration, such as suitable forms of a tablet, a capsule, a powder, a granule, a pellet, a troche, a dragee, a pill or lozenge, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion, an elixir, a syrup, etc., or be administered parenterally in the form of injections.
  • Other pharmaceutical compositions that may be administered parenterally include a dispersion, a suspension and an emulsion, as well as sterile powders included in a sterile injection solution or dispersion before their use.
  • a depot injection formulation is also included within the scope of the present invention.
  • suitable forms of administration include a suppository, a spray, an ointment, a cream, a gelatin, an inhalant, a skin patch, etc.
  • the composition according to the present invention may be formulated according to various methods known in the art. Also, pharmaceutically available carrier, diluent, excipient or other additives, which are used in general in the art, may be used herein.
  • the carrier is that which generally used in formulations, and includes, but is not particularly limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate, mineral oil, etc.
  • composition of the present invention may further includes a preservative, a stability-improving compound, a viscosity-improving/regulating compound, a solubility-improving compound, a sweetener, a dye, a taste-enhancing compound, an osmosis-inducing salt, a buffer, an antioxidant, etc.
  • the compounds show a desired effect to treat pain, anxiety or depression
  • the compounds may be used in the form of solvates, esters, stereoisomers, etc. including free compounds, pharmaceutically available salts and hydrates.
  • the above-mentioned compounds are all included in the scope of the present invention.
  • the pharmaceutically available salts may include pharmaceutically available acid addition salts.
  • the pharmaceutically available acid addition salts may be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid and phosphorous acid; and non-toxic organic acids such as aliphatic mono and dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acids; and the like.
  • the pharmaceutically available salts includes, but is not particularly limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propionate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluen
  • the present invention provides a method for treating pain, anxiety or depression in mammals, characterized in that an effective amount of the compound is administered to the mammals in need of treatment thereof.
  • the pain which may be treated by the compound of the present invention, includes a wide range of pains such as acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache, etc.
  • the pharmaceutical composition of the present invention is administered as with active component at a unit dose ranging from approximately 20 to 500 mg.
  • the total daily dose may be generally administered at the amount ranging from approximately 10 to 7000 mg, and preferably from 20 to 3500 mg of the active compound of the present invention.
  • the active compound may also be administered at a certain amount out of the dose range under general investigation of the conditions of patients, and also in consideration of the activity of agents to be administered. In this case, the optimum dose amount of such agents in the particular conditions should be determined by routine experimentations.
  • the compound of the present invention may be administered in single or multiple daily doses, and the dose of the compound may be preferably divided into one, two and three times per day.
  • the compound of the present invention may be administered alone or in combination of a pharmaceutically available carrier or an excipient.
  • the pharmaceutical composition according to the present invention may be formulated in a pharmaceutically available carrier or a diluent, as well as in a supplement and an excipient that are widely known in the art.
  • the formulations may be present in dosages suitable for such administration by using the methods known in the field of pharmacology.
  • the prepared intermediate (10 mmol) was dissolved in tetrahydrofuran (15 mL), and 1,1′-carbonyldiimidazole (20 mmol) was added to the intermediate mixture.
  • the resulting intermediate mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the intermediate mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours.
  • the resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloroacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-dimethylaminoacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroaminoacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butylacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoroacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloroacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxyacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitroacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-methylacetophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-(2,3-dihydro-benzo[1,4]dioxin-6-yl-1)-piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethoxy-phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-trifluoromethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-chloro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-nitrophenyl-piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-4-chlorophenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,6-dimethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-fluoro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-chloro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-hydroxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-pyridylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-( ⁇ -chloro-pyridin-2-yl)-piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dimethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-methylene dioxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dichloro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 5-chloro-2-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,5-dimethoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-piperazin-1-yl-pyrimidine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-4-trifluoromethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-chloro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethyl-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-fluoro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-fluoro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-chloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-difluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting material s.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 1′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dichloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′,5′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-methylenedioxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-hydroxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloroacetophenone and 4-hydroxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-ethoxy-phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 5-chloro-2-methoxy phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 3,4-dichloro phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-methoxy phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methoxy phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-nitro phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methyl phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-fluoro phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of ⁇ -tetralone and 4-methoxy phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro acetophenone and 2-methoxy phenyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-hydroxy phenyl piperazine as starting materials.
  • the compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and potassium carbonate (K 2 CO 3 , 2.4 mmol) and benzylbromide (2.4 mmol) were added thereto, and the resulting mixture was stirred at 70° C. for 10 hours.
  • the reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • the compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and acetylchloride (2.4 mmol) were added thereto, and the resulting mixture was stirred at a room temperature for 5 hours.
  • the reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • the compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and bromopentyl (2.4 mmol) were added thereto, and the resulting mixture was stirred at 80? for 10 hours.
  • the reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • a title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-hydroxy phenyl piperazine as starting materials.
  • the compound 'carbamic aid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (0.6 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (1.2 mmol) was added and acetylchloride (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours.
  • the reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • the prepared crude compound (2 mmol) was dissolved in tetrahydrofuran (10 mL), and 1,1′-carbodiimidazole (4 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 1 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was then stirred at a room temperature for 1 hour.
  • the reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and phenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-methoxyphenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-pyridylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 1-(3-chloro-pyridin-2-yl)-piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and 3,4-methylene dioxy benzylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzoyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzyl piperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-chlorophenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-fluorophenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-hydroxyphenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 101 except for the use of (S)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
  • the purified compound (3.1 mmol) was dissolved in methanol, and subject to the hydrogenation reaction at the presence of platinum catalyst to obtain an amino compound with a reduced nitro group.
  • the prepared compound (1.21 mmol) was dissolved in tetrahydrofuran (20 mL), and triethylamine (3 mmol) was added, and phosgene (a 2.4 M toluene solution, 1.21 mmol) was added slowly to the mixture. In this case, a temperature of the reaction product was carefully maintained in a temperature range of no more than 10° C.
  • the reaction product was stirred at a room temperature for 16 hours, diluted with ammonium hydroxide, and then extracted several times with ethyl acetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and re-crystallized from ethyl acetate to prepare a final compound.
  • Phenyl-1-propenyl-ketone (4.1 mmol) and 4-methoxy phenylpiperazine (4.9 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was stirred at 72° C. for 48 hours.
  • the mixture was distilled under a reduced pressure, diluted with water, and then extracted twice with ethyl acetate.
  • the prepared crude compound (2.9 mmol) was dissolved in methanol (20 mL), and NaBH 4 (3.8 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hour, and concentrated under a reduced pressure, and obtained a yellow pellet.
  • the resulting mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours.
  • the resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-chlorophenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-nitrophenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethylphenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2-piperazin-1-yl-quinoxaline as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethoxyphenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,5-dichloropyridylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dichlorophenylpiperazine as starting materials.
  • a title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2,4-difluorophenylpiperazine as starting materials.
  • the prepared pellet (1.75 mmol) was dissolved in tetrahydrofuran (20 mL), and 1.5 mole of a cyclohexanelithium diimide (1.92 mmol) solution was added dropwise while the resulting mixture was maintained to a temperature of ⁇ 78° C. Then, the resulting mixture was stirred at ⁇ 78° C. for 10 minutes, and then stirred at 0° C. for 30 minutes. After the resulting mixture was cooled again and maintained to a temperature of ⁇ 78° C., N-fluorobenzenesulfonimide (2.27 mmol) was added to the mixture, and the resulting mixture was stirred at a room temperature for 2 hours.
  • the prepared crude compound (1.5 mmol) was dissolved in methanol (20 mL), and NaBH 4 (3.0 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 1 hour, and concentrated under a reduced pressure to remove off solvents.
  • the prepared crude compound (1 mmol) was dissolved in tetrahydrofuran (20 mL), and 1,1′-carbodiimidazole (2 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 2 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours.
  • the resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase.
  • the prepared organic phase was dried over magnesium sulfate, and then concentrated under a reduced pressure.
  • An acetic acid-induced writhing test is one of models for measuring an analgesic effect of drugs.
  • a test material dissolved in a suitable vehicle was orally administered to a male ICR mouse weighing 30 to 35 g at an amount of 10 mg/kg.
  • 10 mg/ml of an aqueous 0.8% acetic acid solution was intraperitoneally injected into the male ICR mouse to induce the abdominal pain of the male ICR mouse.
  • the male ICR mouse was put into an empty cage, and the number of writhing behaviors of the mice was counted for 10 minutes.
  • the term “writhing represents a reflex action in which the mouse overtly extends its abdomen by stretching its hind legs due to the abdominal pain.
  • the analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ ⁇ [(Writhing number of Vehicle-administered group ⁇ Writhing number of Test material-administered group)/(Writhing number of Vehicle-administered group)] ⁇ 100% ⁇ or 50% of Effective amount (ED 50 (median effective dose); an amount of test material that is required to suppress 50% of pain behaviors) of Test material.
  • ED 50 median effective dose
  • the ED 50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED 50 value.
  • a formalin test is another model for measuring an analgesic effect of drugs.
  • a formalin solution was subcutaneously administered into the planta surface of a mouse's hindlimb, the mouse shows specific pain behaviors such as immediately holding up and down, flinching and licking a mouse's left foot.
  • These pain behaviors have a biphasic pattern, and therefore they are divided into an early-phase behavior within 10 seconds after the formalin administration; and a late-phase behavior up to 10 to 60 minutes.
  • the medicinal effect observed in the formalin test-late phase means an analgesic effect of the test material in the inflammatory pain model, and also becomes a measure that may predict the medicinal effects in the neuropathic pain model (Vissers K et. al, 2003).
  • test material was orally administered to a male ICR mouse weighing 30 to 35 g. After 1 hour of the oral administration, 20 ⁇ l of a 2.5% formalin solution was subcutaneously injected into the planta surface of a mouse's hindlimb to induce pain. After 20 minutes of the administration of the formalin solution, the time when the mouse shows the pain behaviors (flinching, licking, etc.) was recorded for 15 minutes, and quantified.
  • the analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ ⁇ [(Pain response time of Vehicle-administered group ⁇ Pain response time of Test material-administered group)/(Pain response time of Vehicle-administered group)] ⁇ 100% ⁇ , or ‘50% of Effective amount (ED 50 ; an amount of a test material that is required to suppress 50% of pain behaviors) of Test material’.
  • the ED 50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED 50 value.
  • serotonin (5-HT) receptors are closely related to the induction of various psychiatry disorders, for example, depression, anxiety, schizophrenia, phobia, obsession, migraine headache, panic disorder, etc.
  • the serotonin receptor is divided into subtypes including 5-HT1, 5-HT2, 5HT3, 5-HT4, 5-HT6, 5-HT7, etc.
  • the 5-HT1 receptor is divided into subtypes: 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F etc. From the preclinical electrophysiologic test, it was found that the 5-HT1A receptor of postsynaptic neuron is associated with the anti-depression effect.
  • the 5-HT2A receptor tends to sharply decrease from adolescence to middle age of a normal human, and to slowly decrease after the middle age.
  • a level of the 5-HT2A receptor in an elderly patient suffering from depression is very lower than that of the normal human, and therefore it was found that the deficiency of serotonin in a wide region of brain may be one cause of the depression in the elderly.
  • the above-mentioned compounds were tested for medicinal effects against depression and anxiety through their binding to the 5-HT1A receptor and the 5-HT2A receptor.
  • nM [3H]-Ketanserin was used as a radioactive isotope, and 10 uM serotonin was used to remove non-specific bindings.
  • 25 ul of the compound, 100 ul of an aqueous radioactive isotope solution, and 100 ul of the protein source were put together, and kept at 25° C. for 1 hour.
  • the resulting mixture was filtered with a membrane filter in a 96-well harvester when the 96-well plate reaction was completed.
  • the competitivity of the compound to [3H]-Ketanserin was determined by taking the membrane filter and measuring the radioactivity in a scintillation counter, and an IC 50 value was determined by measuring the increasing concentration of the compound.
  • the compound of the present invention is administered to patient, alone or in combinations with pharmaceutically available carriers.
  • An exact dose of the administered compound may be determined according to the conditions of patients, the severity of patient status and the activity of the compound. Under the specific circumstances, the optimum dose of the administered compound should essentially be determined in a clinical manner, but be present within the scope of the present invention.
  • the compound is preferably administered orally since the compound is easily absorbed orally, but the present invention is not particularly limited thereto.
  • the compound represented by Formula 1 is preferably used in combinations with a pharmaceutical carrier.
  • a dose ratio of the carrier to the inventive compound is limited to allow the compound to take an effect on patients, and may be widely varied, depending on whether the composition is filled into a capsule, or formulated into a tablet.
  • edible and pharmaceutical carriers or mixtures thereof may be used herein.
  • the suitable carriers includes, but are not particularly limited to, lactose, dibasic calcium phosphate and/or corn starch, and mixtures thereof, etc.
  • Other pharmaceutically available compounds may be further added, including a lubricant such as magnesium stearate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

There is provided a novel carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain (i.e., acute or chronic pain, neuropathic pain, inflammatory pain, diabetic pain, postherpetic neuralgia, etc.), anxiety or depression including an effective amount of the compound, and a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.

Description

    TECHNICAL FIELD
  • The present invention relates to novel carbamoyloxy arylalkan arylpiperazine compound, a pharmaceutical compositions comprising the compound and a method for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression in mammals by administering the compound to the mammals in need of treatment thereof.
    • BACKGROUND ART
  • Up to now, arylpiperazine compounds were proven to be effective to a variety of indications in the field of central nervous system. In particular, U.S. Pat. No. 3,002,976 reported that the following thiophene-engrafted arylpiperazine compound has a pharmacological effect to treat depression. In this formula, R represents hydrogen, methyl group or halogen.
    Figure US20120095007A2-20120419-C00001
  • Also, it has been known that effects of buspirone and its structurally related compounds on the treatment of anxiety is due to their selective activities in serotonin (5-hydroxytryptamine: 5HT) sub-type receptor represented by a receptor 5-HT1A. In particular, U.S. Pat. No. 4,988,814 discloses piperazine derivatives showing affinity to the 5-HT1A receptor characterized as therapeutic agents to treat depression and anxiety.
    Figure US20120095007A2-20120419-C00002
  • wherein, R1 is alkyl having carbon atoms of 1 to 6; R2 and R3 are each independently alkyl having carbon atoms of 1 to 6, or R2 and R3 are taken together to form polymethylene having carbon atoms of 2 to 12 or to form a 5-norbornen-2-yl residue with carbon atoms bount to the radicals R2 and R3; X is selected from the group consisting of —CO2—, —OCO—, —OCO2—, —N(R7)CO—, —NHNHCO—, —ON(R7)CO—, —CON(R7)—, —N(R7)CO2—, —OCON(R7)— and —N(R7)CON(R8) (wherein, R7 and R8 are each independently is selected from the group consisting of hydrogen; alkyl having carbon atoms of 1 to 6; phenyl; benzyl; and phenyl or benzyl substituted by halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, cyano, nitro or perhalomethyl); R4 is hydrogen or alkyl having carbon atoms of 1 to 6; R5 is selected from the group consisting of hydrogen; alkyl having carbon atoms of 1 to 8; hydroxyalkyl having carbon atoms of 1 to 3; phenyl; benzyl; and phenyl or benzyl substituted by hydroxy, halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, trifluoromethyl, nitro, cyano, carbalkoxy having carbon atoms of 2 to 7, carboxamido, amino, alkylamino having carbon atoms of 1 to 6 or dialkylamino having carbon atoms of 2 to 12; R6 is phenyl, benzyl, 2-, 3- or 4-pyridinyl, 2-pyrimidinyl or 2-pyrazinyl that may be substituted by at least one substituents selected from the group consisting of hydroxy, halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, trifluoromethyl, nitro, cyano, carbalkoxy having carbon atoms of 2 to 7, carboxamido, amino, alkylamino having carbon atoms of 1 to 6, and dialkylamino having carbon atoms of 2 to 12; n is one integer selected from the group consisting of 0, 1, 2, 3, 4 and 5, provided that R6 is not 2-pyrimidinyl when X is —CON(R7)— (wherein, R7 is alkyl), and R6 is not 3,5-di(trifluoromethyl)phenyl when X is —CO2, R1, R2 and R3 are methyl and n is 1.
  • The present inventors have confirmed that an arylpiperazine structure is correlated with an effect to treat pains as well as anxiety and depression, conducted comprehensive researches on the arylpiperazine structure, and found that novel carbamoyloxy arylalkan arylpiperazine compounds have a medical effect in various pain-induced animal models. In particular, the present inventors have found that the novel carbamoyloxy arylalkan arylpiperazine compounds show their therpeutic effects to treat a wide scope of pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression. Therefore, the present invention was completed on the basis of the above-mentioned facts.
    • DISCLOSURE OF INVENTION Technical Problem
  • An aspect of the present invention provides a novel carbamoyloxy arylalkan arylpiperazine derivative compound and pharmaceutically available salts or hydrates thereof.
  • Another aspect of the present invention provides a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound.
  • Still another aspect of the present invention provides a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.
    • Technical Solution
  • According to an aspect of the present invention, there is provided a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
    Figure US20120095007A2-20120419-C00003
  • wherein, - - - may selectively form a cyclic ring;
  • R1 and R2 are hydrogen, or R1 or R2 may be taken together with X1 to form a bicyclic ring;
  • X1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
  • Z is hydrogen or fluorine, or may be taken together with X1 to form a bicyclic ring;
  • Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline;
  • Y1 and Y2 are each independently hydrogen or methyl (CH3);
  • Y3 is hydrogen, phenyl, or carbonyl (═O);
  • Y4 is hydrogen, or methyl (CH3);
  • n is integer of 1 or 2;
  • m is integer of 0 or 1.
  • According to another aspect of the present invention, there is provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound having abundant racemic or enantiomeric characteristics.
  • According to still another aspect of the present invention, there is provided a method for treating pain, anxiety or depression in mammals by administering to the mammals in need of treatment thereof an effective amount of the compound having abundant racemic or enantiomeric characteristics.
    • Advantageous Effects
  • As described above, the novel carbamoyloxy arylalkan arylpiperazine derivative compound, and salts and hydrates thereof according to the present invention may be effectively used as a therapeutic agent for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain and migraine headache, anxiety and depression.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Hereinafter, the present invention will be described in more detail.
  • The present invention is related to a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
    Figure US20120095007A2-20120419-C00004
  • wherein, - - - may selectively form a cyclic ring;
  • R1 and R2 are hydrogen, or R1 or R2 may be taken together with X1 to form a bicyclic ring;
  • X1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
  • Z is hydrogen or fluorine, or may be taken together with X1 to form a bicyclic ring;
  • Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline,
  • Y1 and Y2 are each independently hydrogen or methyl (CH3);
  • Y3 is hydrogen, phenyl, or carbonyl (═O);
  • Y4 is hydrogen, or methyl (CH3);
  • n is integer of 1 or 2;
  • m is integer of 0 or 1.
  • The compounds according to one exemplary embodiment of the present invention may be chemically synthesized as in the following Schemes 1 to 3. However, they are described for the purpose of illustrations only, and the present invention is not particularly limited thereto.
  • In the following Schemes, HX represents acid that may form pharmaceutically available salts with a compound having basic nitrogen. The acid includes, but is not particularly limited to, for example, hydrochloric aid, sulfuric aid, phosphoric acid, acetic acid, benzoic acid, citric acid, malonic acid, salicylic acid, malic acid, fumaric acid, oxalic acid, succinic acid, tartaric aid, lactic acid, gluconic acid, ascorbic acid, maleic acid, aspartic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxymethanesulfonic acid, hydroxyethanesulfonic acid, etc. Additional acids may refer to a literature [“Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66(1): 1-19]. The preparation of the compound of the present invention is carried out in a reaction medium that may be illustrated as an ether solvent (tetrahydrofuran, ethylether, propylether, isopropylether, and butylether), an alcohol solvent (methanol, ethanol, and isopropyl alcohol), an ester solvent (ethyl acetate), a halogenated hydrocarbon solvent (dichloromethane, chloroform) and mixtures thereof.
    Figure US20120095007A2-20120419-C00005
  • As shown in the Scheme 1, a compound (1-3) was synthesized at the presence of a starting material (1-1) substituted by X1 and phenylpiperazine (1-2) substituted by X2 through a Mannich reaction. A compound (1-4) was prepared by reducing the compound (1-3) with sodium borohydride (NaBH4), reacted with 1,1-carbonyl dimidazole (CDI), and then reacted with various amines (NHR1R2) to obtain a compound (1-5) and its salt (1-6).
  • The reaction product (1-5) or its salt (1-6) prepared through the Scheme 1 was obtained in the form of a racemic compound.
    Figure US20120095007A2-20120419-C00006
  • As shown in the Scheme 2, a compound (2-3) engrafted by various kinds of piperazine derivatives (2-2) was prepared from a starting material '3-chloro-1-phenyl-propan-1-ol (compound (2-1) if n=1) or '4-chloro-1-phenyl-butan-1-ol (compound (2-1) if n=2), reacted with 1,1-carbonyl dimidazole (CDI), and then reacted with amines (NHR1R2) to obtain a compound (2-4) and its salt (2-5).
  • Stereochemistries of the reaction product (2-4) and its salt (2-5) depend only on the starting material (2-1); that is, the reaction product having an (S)-enantiomer only is obtained from the starting material (2-1) having an (S)-enantiomer, and the reaction product having a (R)-enantiomer only is obtained from the starting material (2-1) having a (R)-enantiomer.
    Figure US20120095007A2-20120419-C00007
  • As shown in the Scheme 3, a compound (3-3) was synthesized from phenyl-1-propenylketone (3-1) and substituents-engrafted phenylpiperazine (3-2) through 1,4-Michael addition. The compound (3-3) was subject to the reduction reaction at the presence of sodium borohydride (NaBH4) to obtain a compound (3-4) as an alcohol intermediate, and the compound (3-4) was reacted with 1,1-carbonyl dimidazole (CDI), as described previously above, to obtain a carbamate-engrafted compound (3-5) and its salt (3-6).
  • The reaction products obtained in the Scheme 3 were all obtained in the form of a racemic compound.
  • According to the present invention, there is provided a pharmaceutical composition including an effective amount of the compound to treat pain, anxiety or depression. Here, the pharmaceutical composition includes, as an active component, at least one compound among the compounds as listed in this application, and the composition according to the present invention may include any combination of the compounds according to the present invention.
  • The pharmaceutical composition of present invention may be specifically formulated so that it can be administered via any form, such as suitable routes of administration. Here, the suitable routes of administration may, for example, include oral, rectal, nasal, pulmonary, local, percutaneous, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and transdermal routes) routes. The pharmaceutical composition of present invention is preferably administered via the oral route. The preferred routes of administration will, of course, be varied depending on a variety of factors, including the general conditions and age of the subject being treated, the severity of the conditions being treated, and the selected active components, etc.
  • Pharmaceutical preparations formulated according to the present invention may be administered orally in any form of administration, such as suitable forms of a tablet, a capsule, a powder, a granule, a pellet, a troche, a dragee, a pill or lozenge, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion, an elixir, a syrup, etc., or be administered parenterally in the form of injections. Other pharmaceutical compositions that may be administered parenterally include a dispersion, a suspension and an emulsion, as well as sterile powders included in a sterile injection solution or dispersion before their use. It is considered that a depot injection formulation is also included within the scope of the present invention. Other suitable forms of administration include a suppository, a spray, an ointment, a cream, a gelatin, an inhalant, a skin patch, etc. The composition according to the present invention may be formulated according to various methods known in the art. Also, pharmaceutically available carrier, diluent, excipient or other additives, which are used in general in the art, may be used herein.
  • The carrier is that which generally used in formulations, and includes, but is not particularly limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate, mineral oil, etc. The composition of the present invention may further includes a preservative, a stability-improving compound, a viscosity-improving/regulating compound, a solubility-improving compound, a sweetener, a dye, a taste-enhancing compound, an osmosis-inducing salt, a buffer, an antioxidant, etc.
  • Where the above-mentioned compounds show a desired effect to treat pain, anxiety or depression, the compounds may be used in the form of solvates, esters, stereoisomers, etc. including free compounds, pharmaceutically available salts and hydrates. Also, the above-mentioned compounds are all included in the scope of the present invention.
  • According to the present invention, the pharmaceutically available salts may include pharmaceutically available acid addition salts. The pharmaceutically available acid addition salts may be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid and phosphorous acid; and non-toxic organic acids such as aliphatic mono and dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acids; and the like. Specific examples of the pharmaceutically available salts includes, but is not particularly limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propionate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methane sulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate and mandelate. Particularly, hydrochloric acid and methane sulfonate are preferred.
  • The present invention provides a method for treating pain, anxiety or depression in mammals, characterized in that an effective amount of the compound is administered to the mammals in need of treatment thereof.
  • The pain, which may be treated by the compound of the present invention, includes a wide range of pains such as acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache, etc.
  • In general, the pharmaceutical composition of the present invention is administered as with active component at a unit dose ranging from approximately 20 to 500 mg. The total daily dose may be generally administered at the amount ranging from approximately 10 to 7000 mg, and preferably from 20 to 3500 mg of the active compound of the present invention. However, the active compound may also be administered at a certain amount out of the dose range under general investigation of the conditions of patients, and also in consideration of the activity of agents to be administered. In this case, the optimum dose amount of such agents in the particular conditions should be determined by routine experimentations.
  • The compound of the present invention may be administered in single or multiple daily doses, and the dose of the compound may be preferably divided into one, two and three times per day. The compound of the present invention may be administered alone or in combination of a pharmaceutically available carrier or an excipient. The pharmaceutical composition according to the present invention may be formulated in a pharmaceutically available carrier or a diluent, as well as in a supplement and an excipient that are widely known in the art. For convenience sake, the formulations may be present in dosages suitable for such administration by using the methods known in the field of pharmacology.
    • MODE FOR THE INVENTION
  • Hereinafter, exemplary embodiments of the present invention will be described in detail. However, it should be understood that the description proposed herein is just a preferable example for the purpose of illustrations only, not intended to limit the scope of the invention.
  • 1. Synthesis of Carbamoyloxy Arylalkan Arylpiperazine Compound
    • Example 1 Carbamic acid 1-phenyl-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • Acetophenone (4.67 mmol) and phenylpiperazine (5.61 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was adjusted to pH 2 to 3 by adding concentrated hydrochloric acid dropwise. Paraformaldehyde (46.7 mmol) was added to the mixture, and the resulting mixture was refluxed for 24 hours. The resulting reaction mixture were distilled under a reduced pressure, neutralized with 1 normal sodium chloride aqueous solution, diluted with water, and then extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethyl acetate=1:1 to 1:10). The separated compound (3.5 mmol) was dissolved in methanol (20 mL), and cooled to 0° C., and sodium borohydride (5 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure. Then, the resulting yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1) to obtain an alcohol intermediate. The prepared intermediate (10 mmol) was dissolved in tetrahydrofuran (15 mL), and 1,1′-carbonyldiimidazole (20 mmol) was added to the intermediate mixture. The resulting intermediate mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the intermediate mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1 to hexane:ethylacetate=0:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00008
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 4.92 (br, 2H), 5.75 (t, 1H), 6.89 (m, 4H), 7.11 (m, 5H)
  • Compounds of Examples 2 to 84 were prepared in the same manner as in the Example 1, except that the different starting materials were used in the Examples 2 to 84.
    • Example 2 Carbamic acid 1-(4-chloro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloroacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00009
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.16 (m, 1H), 2.33 (m, 2H), 2.45 (m, 4H), 3.01 (m, 4H), 4.57 (br, 2H), 5.51 (t, 1H), 6.80 (m, 2H), 7.19 (m, 2H), 7.28 (m, 5H)
    • Example 3 Carbamic acid 1-(4-dimethylamino-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-dimethylaminoacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00010
  • 1H NMR (200 MHz, CDCl3) d: 2.62 (m, 3H), 2.71 (m, 1H), 2.82 (m, 2H), 2.94 (dd, 6H), 3.25 (m, 4H), 4.87 (dd, 1H), 5.8 (br, 2H), 6.71 (d, 2H), 6.9 (m, 3H), 7.26 (m, 5H)
    • Example 4 Carbamic acid 1-(3-nitro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroaminoacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00011
  • 1H NMR (200 MHz, CDCl3) d: 2.58 (m, 2H), 2.66 (m, 2H), 2.95 (m, 4H), 3.36 (m, 4H), 4.86 (br, 2H), 5.80 (t, 1H), 6.89-6.97 (m, 3H), 7.29 (m, 2H), 7.54 (t, 1H), 7.75 (d, 1H), 8.15 (q, 1H), 8.29 (d, 1H)
    • Example 5 Carbamic acid 1-(4-tert-butyl-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butylacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00012
  • 1H NMR (200 MHz, CDCl3) d: 1.32 (s, 9H), 3.27 (m, 6H), 3.41 (m, 4H), 3.88 (m, 4H), 4.90 (br, 2H), 5.66 (t, 1H), 6.81 (m, 1H), 7.01 (m, 3H), 7.42 (m, 5H)
    • Example 6 Carbamic acid 1-(4-fluoro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoroacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00013
  • 1H NMR (200 MHz, CDCl3) d: 1.88 (m, 2H), 2.76 (m, 6H), 3.27 (m, 2H), 4.57 (br, 2H), 5.51 (t, 1H), 6.89 (m, 4H), 7.32 (m, 5H)
    • Example 7 Carbamic acid 1-(3-chloro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloroacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00014
  • 1H NMR (200 MHz, CDCl3) d: 1.85 (m, 2H), 2.61-2.84 (m, 6H), 3.27 (m, 4H), 4.83 (br, 2H), 5.79 (t, 1H), 6.89 (m, 3H), 7.21-7.40 (m, 6H)
    • Example 8 Carbamic acid 1-(4-methoxy-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxyacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00015
  • 1H NMR (200 MHz, CDCl3) d: 2.56 (m, 2H), 2.65 (m, 4H), 2.93 (m, 2H), 3.25 (m, 4H), 3.81 (s, 3H), 4.77 (t, 1H), 5.02 (br, 2H), 6.91 (m, 5H), 7.29 (m, 4H)
    • Example 9 Carbamic acid 1-(4-nitro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitroacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00016
  • 1H NMR (200 MHz, CDCl3) d: 2.22 (m, 2H), 3.23 (m, 6H), 3.68 (m, 2H), 3.91 (m, 2H), 5.10 (br, 2H), 5.81 (t, 1H), 6.91 (m, 2H), 7.02 (m, 2H), 7.40 (m, 2H), 7.62 (m, 2H), 8.23 (m, 2H)
    • Example 10 Carbamic acid 3-(4-phenyl-piperazin-1-yl)-1-p-tolyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methylacetophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00017
  • 1H NMR (500 MHz, DMSO) d: 2.11 (s, 1H), 2.31 (s, 3H), 2.50 (s, 1H), 3.20 (m, 6H), 3.51 (m, 2H), 5.55 (t, 1H), 6.80 (br, 2H), 6.89 (m, 1H), 7.01 (m, 2H), 7.24 (m, 4H), 7.29 (m, 4H)
    • Example 11 Carbamic acid 3-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-(2,3-dihydro-benzo[1,4]dioxin-6-yl-1)-piperazine as starting materials.
    Figure US20120095007A2-20120419-C00018
  • 1H NMR (200 MHz, CDCl3) d: 2.03 (m, 1H), 2.21 (m, 1H), 2.42 (m, 2H), 2.55 (m, 4H), 3.05 (m, 4H), 4.20 (m, 4H), 4.80 (br, 2H), 5.82 (t, 1H), 6.45 (m, 2H), 6.84 (m, 1H), 7.32 (m, 5H)
    • Example 12 Carbamic acid 1-phenyl-3-[4-(4-trifluoromethoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethoxy-phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00019
  • 1H NMR (200 MHz, CDCl3) d: 2.12 (m, 2H), 2.41 (m, 2H), 2.56 (m, 4H), 3.17 (m, 4H), 4.65 (br, 2H), 5.90 (t, 1H), 6.86 (m, 2H), 7.11 (m, 2H), 7.31 (m, 5H)
    • Example 13 Carbamic acid 3-[4-(2,4-dimethyl-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00020
  • 1H NMR (200 MHz, CDCl3) d: 1.97-2.10 (m, 1H), 2.13-2.24 (m, 1H), 2.29 (s, 3H), 2.30 (s, 3H), 2.43-2.51 (m, 2H), 2.61-2.82 (m, 4H), 2.91-2.95 (m, 4H), 4.84 (br, 2H), 5.76 (t, 1H), 6.94-7.03 (m, 3H), 7.28-7.38 (m, 5H)
    • Example 14 Carbamic acid 1-phenyl-3-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-trifluoromethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00021
  • 1H NMR (200 MHz, Acetone) d: 2.07 (m, 2H), 2.35 (m, 2H), 2.45 (m, 4H), 2.76 (m, 4H), 5.78 (t, 1H), 6.01 (br, 2H), 7.34 (m, 5H), 7.57 (m, 4H)
    • Example 15 Carbamic acid 1-phenyl-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-chloro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00022
  • 1H NMR (200 MHz, Acetone) d: 1.99 (m, 2H), 2.21 (m, 2H), 2.36 (m, 4H), 2.77 (m, 4H), 5.89 (t, 1H), 6.10 (br, 2H), 7.30 (m, 5H), 7.48 (m, 4H)
    • Example 16 Carbamic acid 1-phenyl-3-[4-(4-nitro-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-nitrophenyl-piperazine as starting materials.
    Figure US20120095007A2-20120419-C00023
  • 1H NMR (200 MHz, CDCl3) d: 2.11 (m, 2H), 2.26 (m, 2H), 2.51 (m, 4H), 2.59 (m, 4H), 4.81 (br, 2H), 5.81 (t, 1H), 6.48 (m, 4H), 7.28 (2H), 7.42 (m, 2H)
    • Example 17 Carbamic acid 3-[4-(2,4-dimethoxy-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00024
  • 1H NMR (200 MHz, CDCl3) d: 2.06 (m, 1H), 2.18 (m, 1H), 2.45 (m, 3H), 2.64 (m, 4H), 3.03 (m, 4H), 3.79 (s, 3H), 3.84 (s, 3H), 3.84 (s, 3H), 4.73 (br, 2H), 5.87 (t, 1H), 6.48 (m, 2H), 6.86 (d, 1H), 7.28-7.37 (m, 5H)
    • Example 18 Carbamic acid 3-[4-(4-chloro-3-trifluoromethyl-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-4-chlorophenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00025
  • 1H NMR (200 MHz, CDCl3) d: 2.03 (m, 1H), 2.18 (m, 1H), 2.44 (m, 2H), 2.60 (m, 4H), 3.23 (m, 4H), 4.71 (br, 2H), 5.78 (t, 1H), 6.96 (m, 1H), 7.28-7.32 (m, 7H)
    • Example 19 Carbamic acid 3-[4-(2,6-dimethyl-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,6-dimethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00026
  • 1H NMR (200 MHz, CDCl3) d: 2.05 (m, 1H), 2.18 (m, 1H), 2.27 (s, 6H), 2.41 (m, 2H), 2.55 (m, 4H), 3.13 (m, 4H), 4.70 (br, 2H), 5.77 (t, 1H), 6.97-6.99 (m, 3H), 7.28-7.39 (m, 5H)
    • Example 20 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00027
  • 1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
    • Example 21 Carbamic acid 3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-fluoro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00028
  • 1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
    • Example 22 Carbamic acid 3-[4-(4-chloro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-chloro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00029
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.67 (br, 2H), 5.76 (t, 1H), 6.85 (m, 2H), 7.24 (m, 2H), 7.37 (m, 5H)
    • Example 23 Carbamic acid 3-[4-(2-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-hydroxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00030
  • 1H NMR (200 MHz, CDCl3) d: 2.05 (m, 2H), 2.40 (m, 2H), 2.62 (m, 4H), 2.90 (m, 4H), 4.63 (br, 2H), 5.71 (t, 1H), 6.96 (m, 3H), 7.14 (m, 2H), 7.35 (m, 3H)
    • Example 24 Carbamic acid 1-phenyl-3-(4-m-tolyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00031
  • 1H NMR (200 MHz, Acetone) d: 2.07 (m, 2H), 2.28 (s, 3H), 2.39 (m, 2H), 2.55 (m, 4H), 3.17 (m, 4H), 5.81 (t, 1H), 6.61 (br, 2H), 6.78 (m, 2H), 7.10 (t, 1H), 7.31-7.40 (m, 5H)
    • Example 25 Carbamic acid 1-phenyl-3-(4-pyridin-2-yl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-pyridylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00032
  • 1H NMR (200 MHz, CDCl3) d: 2.19 (m, 2H), 2.32 (m, 2H), 2.48 (m, 4H), 2.67 (m, 4H), 4.84 (br, 2H), 5.79 (t, 1H), 6.89 (m, 1H), 7.19 (m, 1H), 7.34 (m, 3H), 7.56 (m, 3H), 8.11 (m, 1H)
    • Example 26 Carbamic acid 3-[4-(3-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00033
  • 1H NMR (200 MHz, CDCl3) d 1.97 (m, 2H), 2.39 (m, 2H), 2.55 (m, 4H), 3.18 (m, 4H), 3.77 (s, 3H), 5.76 (t, 1H), 6.1 (br, 2H), 6.43 (m, 1H), 6.53 (m, 1H), 7.12 (t, 1H), 7.30-7.43 (m, 5H)
    • Example 27 Carbamic acid 3-[4-(2-methoxy-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00034
  • 1H NMR (200 MHz, CDCl3) d: 1.88 (m, 2H), 2.29 (m, 2H), 2.46 (m, 4H), 3.09 (m, 4H), 3.82 (s, 3H), 5.66 (t, 1H), 5.90 (br, 2H), 6.82 (m, 4H), 7.29 (m, 5H)
    • Example 28 Carbamic acid 3-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-(β-chloro-pyridin-2-yl)-piperazine as starting materials.
    Figure US20120095007A2-20120419-C00035
  • 1H NMR (200 MHz, Acetone) d: 1.58 (m, 2H), 1.89 (m, 2H), 2.42 (m, 2H), 2.54 (m, 4H), 3.32 (m, 4H), 5.69 (t, 1H), 6.07 (br, 2H), 6.95 (m, 1H), 7.27-7.39 (m, 5H), 7.71 (m, 1H), 8.21 (m, 1H)
    • Example 29 Carbamic acid 3-[4-(3,4-dimethyl-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dimethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00036
  • 1H NMR (200 MHz, CDCl3) d: 2.01 (m, 2H), 2.17 (s, 3H), 2.21 (s, 3H), 2.40 (m, 2H), 2.57 (m, 4H), 3.13 (m, 4H), 4.78 (br, 2H), 5.82 (t, 1H), 6.82 (m, 2H), 7.01 (m, 1H), 7.33 (m, 5H)
    • Example 30 Carbamic acid 3-(4-benzo[1,3]dioxol-5-yl-piperazin-1-yl)-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-methylene dioxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00037
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.12 (m, 1H), 2.36 (m, 2H), 2.54 (m, 4H), 3.05 (m, 4H), 4.77 (br, 2H), 5.72 (t, 1H), 5.90 (s, 2H), 6.32 (dd, 1H), 6.55 (m, 1H), 6.72 (d, 1H), 7.33 (m, 5H)
    • Example 31 Carbamic acid 3-[4-(3,4-dichloro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dichloro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00038
  • 1H NMR (200 MHz, CDCl3) d: 2.10 (m, 2H), 2.39 (m, 2H), 2.54 (m, 4H), 3.15 (m, 4H), 4.62 (br, 2H), 5.85 (t, 1H), 6.81 (dd, 1H), 6.99 (m, 1H), 7.34 (m, 6H)
    • Example 32 Carbamic acid 3-[4-(5-chloro-2-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 5-chloro-2-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00039
  • 1H NMR (200 MHz, CDCl3) d: 2.04 (m, 2H), 2.41 (m, 2H), 2.61 (m, 4H), 3.06 (m, 4H), 3.82 (s, 3H), 4.62 (br, 2H), 5.82 (t, 1H), 6.71 (d, 1H), 6.99 (m, 2H), 7.34 (m, 5H)
    • Example 33 Carbamic acid 3-[4-(3,5-dimethoxy-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,5-dimethoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00040
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.21 (m, 1H), 2.49 (m, 2H), 2.58 (m, 4H), 3.20 (m, 4H), 3.80 (s, 3H), 4.89 (br, 2H), 5.89 (t, 1H), 6.11 (m, 1H), 6.12 (m, 2H), 7.37 (m, 5H)
    • Example 34 Carbamic acid 1-phenyl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-piperazin-1-yl-pyrimidine as starting materials.
    Figure US20120095007A2-20120419-C00041
  • 1H NMR (200 MHz, CDCl3) d: 2.00 (m, 2H), 2.44 (m, 6H), 3.83 (m, 4H), 4.79 (br, 2H), 5.45 (t, 1H), 6.49 (t, 1H), 7.31 (m, 5H), 8.31 (m, 2H)
    • Example 35 Carbamic acid 3-[4-(2-nitro-4-trifluoromethyl-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-4-trifluoromethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00042
  • 1H NMR (200 MHz, CDCl3) d: 2.10 (m, 2H), 2.21 (m, 2H), 2.59 (m, 4H), 3.19 (m, 4H), 4.62 (br, 2H), 5.81 (t, 1H), 7.36 (m, 5H), 7.41 (m, 1H), 7.62 (m, 1H), 8.09 (s, 1H)
    • Example 36 Carbamic acid 3-[4-(3-chloro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-chloro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00043
  • 1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
    • Example 37 Carbamic acid 1-phenyl-3-(4-o-tolyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00044
  • 1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.19 (s, 3H), 2.37 (m, 2H), 2.58 (m, 4H), 2.89 (m, 4H), 5.78 (t, 1H), 6.2 (br, 2H), 6.92 (t, 1H), 7.19 (m, 3H), 7.31-7.40 (m, 5H)
    • Example 38 Carbamic acid 1-phenyl-3-(4-p-tolyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00045
  • 1H NMR (200 MHz, Acetone) d: 2.08 (m, 2H), 2.10 (s, 3H), 2.29 (m, 2H), 2.55 (m, 4H), 3.13 (m, 4H), 5.76 (t, 1H), 6.01 (br, 2H), 6.85 (m, 2H), 7.03 (m, 5H), 7.31-7.40 (m, 5H)
    • Example 39 Carbamic acid 1-phenyl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00046
  • 1H NMR (200 MHz, Acetone) d: 2.03 (m, 2H), 2.42 (m, 2H), 2.58 (m, 4H), 3.29 (m, 4H), 5.78 (t, 1H), 6.01 (br, 2H), 7.09 (m, 1H), 7.23 (m, 2H), 7.30-7.43 (m, 6H)
    • Example 40 Carbamic acid 1-phenyl-3-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethyl-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00047
  • 1H NMR (200 MHz, Acetone) d: 2.41 (m, 2H), 2.57 (m, 4H), 2.83 (m, 2H), 3.34 (m, 4H), 5.77 (t, 1H), 5.97 (br, 2H), 7.09 (m, 2H), 7.36 (m, 5H), 7.52 (m, 2H)
    • Example 41 Carbamic acid 3-[4-(2-fluoro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-fluoro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00048
  • 1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.38 (m, 2H), 2.58 (m, 4H), 3.09 (m, 4H), 5.77 (t, 1H), 5.89 (br, 2H), 7.06 (m, 4H), 7.30-7.40 (m, 5H)
    • Example 42 Carbamic acid 3-[4-(3-fluoro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-fluoro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00049
  • 1H NMR (200 MHz, Acetone) d: 2.08 (m, 2H), 2.39 (m, 2H), 2.56 (m, 4H), 3.22 (m, 4H), 5.80 (t, 1H), 6.17 (br, 2H), 6.62 (m, 1H), 6.78 (m, 2H), 7.20-7.45 (m, 6H)
    • Example 43 Carbamic acid 3-[4-(2-nitro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00050
  • 1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.40 (m, 2H), 2.44-2.62 (m, 4H), 3.07 (m, 4H), 5.77 (t, 1H), 5.98 (br, 2H), 7.32 (m, 1H), 7.57-7.76 (m, 2H)
    • Example 44 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-(4-nitro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00051
  • 1H NMR (200 MHz, CDCl3) d: 1.95 (m, 1H), 2.17 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.78 (s, 3H), 4.91 (br, 2H), 5.83 (t, 1H), 6.88 (m, 4H), 7.53 (d, 2H), 8.23 (d, 2H)
    • Example 45 Carbamic acid 1-(3-chloro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00052
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.20 (m, 1H), 2.43 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.75 (br, 2H), 5.73 (t, 1H), 6.89 (m, 4H), 7.32 (m, 4H)
    • Example 46 Carbamic acid 1-(2-fluoro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00053
  • 1H NMR (200 MHz, CDCl3) d: 1.88-2.00 (m, 2H), 2.32 (m, 2H), 2.58 (m, 4H), 3.09 (m, 4H), 3.81 (s, 3H), 4.89 (br, 2H), 5.81 (t, 1H), 6.92 (m, 4H), 7.28 (m, 5H)
    • Example 47 Carbamic acid 1-(4-methoxy-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00054
  • 1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.17 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.78 (s, 3H), 3.81 (s, 3H), 4.87 (br, 2H), 5.69 (t, 1H), 6.88 (m, 6H), 7.30 (m, 2H)
    • Example 48 Carbamic acid 1-(4-tert-butyl-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00055
  • 1H NMR (200 MHz, CDCl3) d: 1.32 (s, 9H), 1.94 (m, 2H), 2.68 (m, 3H), 2.80 (m, 3H), 3.27 (m, 4H), 3.78 (s, 3H), 4.95 (t, 1H), 5.82 (br, 2H), 6.90 (m, 3H), 7.24-7.38 (m, 6H)
    • Example 49 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-naphthalen-2-yl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00056
  • 1H NMR (200 MHz, CDCl3) d: 2.08 (m, 1H), 2.43 (m, 1H), 2.47 (m, 2H), 2.55 (m, 4H), 3.12 (m, 4H), 3.79 (s, 3H), 4.7 (br, 2H), 5.93 (t, 1H), 6.89 (m, 4H), 7.51 (m, 3H), 7.86 (m, 4H)
    • Example 50 Carbamic acid 1-(2-chloro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-chloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00057
  • 1H NMR (200 MHz, CDCl3) d: 2.08 (m, 2H), 2.58 (m, 5H), 3.10 (m, 4H), 3.78 (s, 3H), 4.85 (br, 2H), 6.12 (t, 1H), 6.82-6.94 (m, 4H), 7.21-7.45 (m, 4H)
    • Example 51 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-(2-trifluoromethyl-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00058
  • 1H NMR (200 MHz, CDCl3) d: 2.04 (m, 2H), 2.63 (m, 6H), 3.11 (m, 4H), 3.79 (s, 3H), 4.78 (br, 2H), 6.12 (t, 1H), 6.83-6.95 (m, 4H), 7.37-7.69 (m, 4H)
    • Example 52 Carbamic acid 1-(3,4-difluoro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-difluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00059
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.80 (s, 3H), 4.92 (br, 2H), 5.75 (t, 1H), 6.89 (m, 4H), 7.11 (m, 3H)
    • Example 53 Carbamic acid 1-(3-fluoro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00060
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.19 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 4.88 (br, 2H), 5.74 (t, 1H), 6.91 (m, 4H), 7.10 (m, 3H), 7.33 (m, 1H)
    • Example 54 Carbamic acid 1-(3-methoxy-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting material s.
    Figure US20120095007A2-20120419-C00061
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.14 (m, 1H), 2.44 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 3.82 (s, 3H), 4.86 (br, 2H), 5.72 (t, 1H), 6.83 (m, 7H), 7.28 (m, 1H)
    • Example 55 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-naphthalen-1-yl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 1′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00062
  • 1H NMR (200 MHz, CDCl3) d: 2.26 (m, 2H), 2.55 (m, 2H), 2.63 (m, 4H), 3.12 (m, 4H), 3.80 (s, 3H), 4.71 (br, 2H), 6.59 (t, 1H), 6.92 (m, 4H), 7.45-7.58 (m, 4H), 7.62-7.92 (m, 2H), 8.25 (d, 1H)
    • Example 56 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-p-tolyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00063
  • 1H NMR (200 MHz, CDCl3) d: 2.17 (m, 2H), 2.36 (s, 3H), 2.42 (m, 2H), 2.64 (m, 4H), 3.12 (m, 4H), 3.78 (s, 3H), 4.78 (br, 2H), 5.87 (t, 1H), 6.88 (m, 4H), 7.23 (m, 4H)
    • Example 57 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-m-tolyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00064
  • 1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.178 (m, 1H), 2.37 (s, 3H), 2.42 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.86 (br, 2H), 5.72 (t, 1), 6.89 (m, 4H), 7.18 (m, 4H)
    • Example 58 Carbamic acid 1-(2,4-dichloro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dichloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00065
  • 1H NMR (200 MHz, CDCl3) d: 2.06 (m, 2H), 2.50 (m, 2H), 2.6 (m, 2H), 3.1 (m, 4H), 3.78 (s, 3H), 4.76 (br, 2H), 6.07 (t, 1H), 6.88 (m, 4H), 7.32 (m, 3H)
    • Example 59 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-o-tolyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00066
  • 1H NMR (200 MHz, CDCl3) d: 1.95-2.03 (m, 1H), 2.06-2.13 (m, 1H), 2.45 (s, 3H), 2.5-2.63 (m, 4H), 3.08-3.13 (m, 4H), 3.79 (s, 3H), 4.66 (br, 2H), 6.00 (t, 1H), 6.83-6.95 (m, 4H), 7.18-7.40 (m, 4H)
    • Example 60 Carbamic acid 1-(2,4-dimethyl-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00067
  • 1H NMR (200 MHz, CDCl3) d: 1.94-2.04 (m, 2H), 2.10-2.21 (m, 2H), 2.32 (s, 3H), 2.41 (s, 3H), 2.60-2.63 (m, 4H), 3.08-3.13 (m, 4H), 3.79 (s, 3H), 4.65 (br, 2H), 5.96 (t, 1H), 6.87-7.06 (m, 6H), 7.27 (d, 1H)
    • Example 61 Carbamic acid 1-(3,4-dimethyl-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00068
  • 1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.11 (m, 1H), 2.32 (s, 3H), 2.41 (s, 3H), 2.44 (m, 2H), 2.62 (m, 4H), 3.12 (m, 4H), 3.80 (s, 3H), 4.65 (br, 2H), 5.69 (t, 1H), 6.91 (m, 4H), 7.14 (m, 3H)
    • Example 62 Carbamic acid 1-(2,5-dimethyl-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′,5′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00069
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.09 (m, 2H), 2.54 (m, 3H), 3.10 (m, 4H), 3.80 (s, 3H), 4.75 (br, 2H), 5.96 (t, 1H), 6.88 (m, 4H), 7.03 (dd, 2H), 7.18 (s, 1H)
    • Example 63 Carbamic acid 1-(4-chloro-3-trifluoromethyl-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00070
  • 1H NMR (200 MHz, CDCl3) d: 1.93 (m, 1H), 2.22 (m, 1H), 2.39 (m, 2H), 2.63 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.89 (br, 2H), 5.77 (t, 1H), 6.89 (m, 4H), 7.52 (m, 4H)
    • Example 64 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-(2-nitro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00071
  • 1H NMR (200 MHz, CDCl3) d: 2.07 (m, 2H), 2.62 (m, 6H), 3.09 (m, 4H), 3.78 (s, 3H), 4.80 (br, 2H), 6.27 (t, 1H), 6.88 (m, 4H), 7.45 (m, 1H), 7.64 (d, 2H), 7.98 (d, 1H)
    • Example 65 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-(3-nitro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00072
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 2H), 2.42-2.65 (m, 6H), 3.11 (m, 4H), 3.80 (s, 3H), 5.01 (br, 2H), 6.22 (t, 1H), 6.78 (m, 4H), 7.37 (m, 1H), 7.8 (d, 2H), 7.98 (d, 1H)
    • Example 66 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-(4-trifluoromethyl-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00073
  • 1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.20 (m, 1H), 2.44 (m, 2H), 2.61 (m, 4H), 3.15 (m, 4H), 3.79 (s, 3H), 4.73 (br, 2H), 5.80 (t, 1H), 6.89 (m, 4H), 7.42 (d, 2H), 7.64 (d, 2H)
    • Example 67 Carbamic acid 1-benzol, 3]dioxol-5-yl-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-methylenedioxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00074
  • 1H NMR (200 MHz, CDCl3) d: 1.19 (m, 1H), 2.19 (m, 1H), 2.39 (m, 2H), 2.60 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 4.75 (br, 2H), 5.65 (t, 1H), 5.97 (s, 2H), 6.76-6.94 (m, 7H)
    • Example 68 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]1-(3-trifluoromethyl-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00075
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.22 (m, 1H), 2.39 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.77 (br, 2H) 5.82 (t, 1H), 6.89 (m, 4H), 7.56 (m, 4H)
    • Example 69 Carbamic acid 1-(2-fluoro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00076
  • 1H NMR (200 MHz, CDCl3) d: 2.14 (m, 2H), 2.49 (m, 2H), 2.61 (m, 4H), 3.09 (m, 4H), 3.79 (s, 3H), 4.91 (br, 2H), 6.02 (t, 1H), 6.91 (m, 4H), 7.14 (m, 2H), 7.36 (m, 2H)
    • Example 70 Carbamic acid 1-(3,4-dichloro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00077
  • 1H NMR (200 MHz, CDCl3) d: 2.11 (m, 2H), 2.17 (m, 2H), 2.68 (m, 4H), 3.15 (m, 4H), 3.72 (s, 3H), 4.81 (br, 2H), 5.90 (t, 1H), 6.92 (m, 4H), 7.12 (m, 1H), 7.28 (m, 2H)
    • Example 71 Carbamic acid 1-(4-chloro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00078
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.17 (m, 1H), 2.42 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.80 (s, 3H), 4.83 (br, 2H), 5.87 (t, 1H), 6.89 (m, 4H), 7.32 (m, 4H)
    • Example 72 Carbamic acid 1-(4-chloro-3-trifluoromethyl-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-hydroxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00079
  • 1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.21 (m, 1H), 2.53 (m, 2H), 2.71 (m, 4H), 4.92 (br, 2H), 5.82 (t, 1H), 6.80 (m, 4H), 7.49 (m, 2H), 7.70 (s, 1H)
    • Example 73 Carbamic acid 1-(3,4-dichloro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloroacetophenone and 4-hydroxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00080
  • 1H NMR (200 MHz, CDCl3) d: 2.08 (m, 2H), 2.16 (m, 2H), 2.65 (m, 4H), 3.11 (m, 4H), 4.75 (br, 2H), 5.83 (t, 1H), 6.82 (m, 4H), 7.29 (m, 1H), 7.43 (m, 2H)
    • Example 74 Carbamic acid 3-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-ethoxy-phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00081
  • 1H NMR (200 MHz, CDCl3) d: 1.43 (m, 3H), 2.18 (m, 2H), 2.55-3.05 (m, 10H), 4.11 (m, 2H), 5.76 (t, 1H), 5.99 (br, 2H), 7.08 (m, 3H), 7.13 (m, 3H), 7.44 (m, 2H)
    • Example 75 Carbamic acid 3-[4-(5-chloro-2-methoxy-phenyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 5-chloro-2-methoxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00082
  • 1H NMR (200 MHz, CDCl3) d: 2.38 (m, 2H), 2.54 (m, 6H), 3.04 (m, 4H), 3.86 (s, 3H), 5.73 (t, 1H), 5.93 (br, 2H), 6.93 (m, 4H), 7.16 (m, 2H), 7.51 (m, 1H)
    • Example 76 Carbamic acid 3-[4-(3,4-dichloro-phenyl)-piperazin-1-yl]1-(4-fluoro-phenyl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 3,4-dichloro phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00083
  • 1H NMR (200 MHz, CDCl3) d: 2.22 (m, 1H), 2.48 (m, 3H), 2.54 (m, 6H), 3.24 (m, 2H), 5.72 (t, 1H), 5.97 (br, 2H), 6.91 (m, 1H), 7.08 (m, 3H), 7.45 (m, 3H)
    • Example 77 Carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-methoxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00084
  • 1H NMR (200 MHz, CDCl3) d: 1.89 (m, 1H), 2.15 (m, 1H), 2.42 (m, 2H), 2.58 (m, 4H), 3.07 (m, 4H), 3.76 (s, 3H), 4.93 (br, 2H), 5.82 (t, 1H), 6.86 (m, 4H), 7.02 (m, 2H), 7.39 (m, 2H)
    • Example 78 Carbamic acid 1-(4-fluoro-phenyl)-3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methoxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00085
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.20 (m, 1H), 2.43 (m, 2H), 2.97 (m, 4H), 3.11 (m, 4H), 3.87 (s, 3H), 4.62 (br, 2H), 5.87 (t, 1H), 6.89-7.09 (m, 6H), 7.35 (m, 2H)
    • Example 79 Carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-nitro-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-nitro phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00086
  • 1H NMR (200 MHz, CDCl3) d: 2.07 (m, 1H), 2.17 (m, 1H), 2.65 (m, 4H), 3.49 (m, 4H), 4.65 (br, 2H), 5.75 (t, 1H), 6.83 (m, 2H), 6.98 (m, 2H), 7.35 (m, 2H), 8.18 (m, 2H)
    • Example 80 Carbamic acid 1-(4-fluoro-phenyl)-3-(4-o-tolyl-piperazin-1-yl)-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methyl phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00087
  • 1H NMR (200 MHz, CDCl3) d: 2.01 (m, 2H), 2.17 (m, 2H), 2.31 (s, 3H), 2.43 (m, 2H), 2.63 (m, 4H), 2.69 (m, 4H), 4.77 (br, 2H), 5.76 (t, 1H), 7.09 (m, 4H), 7.23 (m, 2H), 7.36 (m, 3H)
    • Example 81 Carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-fluoro phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00088
  • 1H NMR (200 MHz, CDCl3) d: 1.89 (m, 1H), 2.21 (m, 1H), 2.39 (m, 2H), 2.59 (m, 4H), 3.14 (m, 4H), 4.82 (br, 2H), 5.80 (t, 1H), 6.89-7.09 (m, 5H), 7.24 (m, 3H)
    • Example 82 Carbamic acid 2-[4-(4-methoxy-phenyl)-piperazin-1-ylmethyl]-1,2,3,4-tetrahydro-naphthalen-1-yl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of α-tetralone and 4-methoxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00089
  • 1H NMR (200 MHz, CDCl3) d: 1.91 (m, 3H), 2.52 (m, 2H), 2.67 (m, 4H), 2.80 (m, 2H), 3.15 (m, 4H), 3.78 (s, 3H), 4.66 (br, 2H), 6.05 (t, 1H), 6.90 (m, 4H), 7.28 (m, 4H)
    • Example 83 Carbamic acid 1-(4-chloro-phenyl)-3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro acetophenone and 2-methoxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00090
  • 1H NMR (200 MHz, CDCl3) d: 2.28 (m, 2H), 2.39 (m, 2H), 3.09 (m, 4H), 3.23 (m, 4H), 3.70 (s, 3H), 4.99 (br, 2H), 5.88 (t, 1H), 7.11 (m, 4H), 7.31 (m, 4H)
    • Example 84 Carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-hydroxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00091
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.14 (m, 2H), 2.58 (m, 4H), 3.12 (m, 4H), 5.12 (br, 2H), 5.78 (t, 1H), 6.99 (m, 4H), 7.21 (m, 5H)
    • Example 85 Carbamic acid 3-[4-(4-benzyloxyphenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and potassium carbonate (K2CO3, 2.4 mmol) and benzylbromide (2.4 mmol) were added thereto, and the resulting mixture was stirred at 70° C. for 10 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00092
  • 1H NMR (200 MHz, CDCl3) d: 2.05 (m, 1H), 2.17 (m, 1H), 2.37 (m, 2H), 2.65 (m, 4H), 3.14 (m, 4H), 4.65 (br, 2H), 5.04 (s, 2H), 5.87 (t, 1H), 7.29-7.43 (m, 9H)
    • Example 86 Acetic acid 4-[4-(3-carbamoyloxy-3-phenyl-propyl)-piperazin-1-yl]-phenyl ester
  • The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and acetylchloride (2.4 mmol) were added thereto, and the resulting mixture was stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00093
  • 1H NMR (200 MHz, CDCl3) d: 2.04 (m, 1H), 2.17 (m, 1H), 2.29 (s, 3H), 2.43 (m, 2H), 2.61 (m, 4H), 3.19 (m, 4H), 4.74 (br, 2H), 5.75 (t, 1H), 6.95 (m, 4H), 7.33 (m, 5H)
    • Example 87 Carbamic acid 3-[4-(4-cyclopentyloxy-phenyl)-piperazin-1-yl ]-1-phenyl-propyl ester
  • The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and bromopentyl (2.4 mmol) were added thereto, and the resulting mixture was stirred at 80? for 10 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00094
  • 1H NMR (200 MHz, CDCl3) d: 1.61 (m, 3H), 85 (m, 8H), 2.11 (m, 1H), 2.27 (m, 1H), 2.62 (m, 4H), 3.11 (m, 4H), 4.76 (br, 2H), 5.78 (t, 1H), 6.85 (m, 4H), 7.34 (m, 5H)
    • Example 88 Carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester
  • A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-hydroxy phenyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00095
  • 1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.12 (m, 1H), 2.40 (m, 2H), 2.62 (m, 4H), 3.08 (m, 4H), 4.78 (br, 2H), 5.82 (t, 1H), 7.07 (m, 5H), 7.23 (m, 3H)
    • Example 89 1-(4-fluorophenyl)-3-(4-(4-(pivaloyloxy)phenyl)piperazin-1-yl)propyl carbamate
  • The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (2 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (2.4 mmol) was added and trimethyl acetylchloride (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00096
  • 1H NMR (200 MHz, CDCl3) d: 1.35 (m, 9H), 1.97 (m, 1H), 2.21 (m, 1H), 2.42 (m, 2H), 2.64 (m, 4H), 3.17 (m, 4H), 4.90 (br, 2H), 5.75 (t, 1H), 6.94 (m, 4H), 7.08-7038 (m, 4H)
    • Example 90 Carbonic acid 4-{4-[3-carbamoyloxy-3-(4-fluoro-phenyl)-propyl]-piperazin-1-yl}-phenyl ethyl ester
  • The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (0.93 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (1.86 mmol) was added and ethyl chloroformate (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00097
  • 1H NMR (200 MHz, CDCl3) d: 1.40 (m, 3H), 2.04 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.63 (m, 4H), 3.19 (m, 4H), 4.30 (m, 2H), 4.79 (br, 2H), 5.72 (t, 1H), 6.88 (m, 2H), 7.06 (m, 4H), 7.34 (m, 4H)
    • Example 91 Carbonic acid benzyl ester 4-{4-[3-carbamoyloxy-3-(4-fluoro-phenyl)-propyl]-piperazin-1-yl}-phenyl ester
  • The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (1 mmol) prepared in Example 88 was dissolved in acetone (20 mL), and triethylamine (2 mmol) was added and benzyl chloroformate (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00098
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.12 (m, 2H), 2.66 (m, 4H), 3.12 (m, 4H), 3.52 (s, 2H), 4.90 (br, 2H), 5.81 (t, 1H), 6.89 (m, 4H), 7.33 (m, 9H)
    • Example 92 Acetic acid 4-{4-[3-carbamoyloxy-3-(4-fluoro-phenyl)-propyl]-piperazin-1-yl}-phenyl ester
  • The compound 'carbamic aid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (0.6 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (1.2 mmol) was added and acetylchloride (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00099
  • 1H NMR (200 MHz, CDCl3) d: 2.02 (m, 1H), 2.17 (m, 1H), 2.38 (s, 3H), 2.42 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.82 (br, 2H), 5.75 (t, 1H), 6.88-7.09 (m, 6H), 7.33 (m, 2H)
    • Example 93 Carbamic acid 3-{4-[bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl}-1-phenyl-propyl ester
  • 3-chloro propiophenone (4 mmol) and 4,4′-bisfluorophenylpiperazine (5.2 mmol) were dissolved in acetonitrile (50 mL), and triethylamine (5.2 mmol) was added dropwise thereto, and the resulting mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethylacetate=1:1). The resulting compound (3.5 mmol) was dissolved in methanol (20 mL), and cooled to 0° C., and sodium borohydride (5 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure, and obtained a yellow pellet. Then, the prepared yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1) to obtain a crude compound.
  • The prepared crude compound (2 mmol) was dissolved in tetrahydrofuran (10 mL), and 1,1′-carbodiimidazole (4 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 1 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was then stirred at a room temperature for 1 hour. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00100
  • 1H NMR (200 MHz, Acetone) d 2.34 (m, 10H), 2.84 (m, 2H), 4.35 (s, 1H), 5.7 (t, 1H), 5.99 (br, 2H), 7.07 (m, 4H), 7.31 (m, 5H), 7.50 (m, 4H)
    • Example 94 Carbamic acid 1-phenyl-4-(4-phenyl-piperazin-1-yl)-butyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and phenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00101
  • 1H NMR (500 MHz, DMSO) d 1.82 (m, 2H), 2.78 (m, 3H), 3.08 (m, 4H), 3.21 (m, 4H), 3.52 (m, 2H), 5.51 (br, 2H), 5.78 (t, 1H), 7.01 (m, 5H), 7.23 (m, 5H)
    • Example 95 Carbamic acid 4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-methoxyphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00102
  • 1H NMR (500 MHz, DMSO) d 1.88 (m, 4H), 3.10-3.30 (m, 6H), 3.52 (m, 4H), 3.80 (s, 3H), 5.42 (br, 2H), 5.51 (t, 1H), 6.91 (m, 1H), 7.01 (m, 2H), 7.09 (m, 1H), 7.33 (m, 5H)
    • Example 96 Carbamic acid 1-phenyl-4-(4-pyridin-2-yl-piperazin-1-yl)-butyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-pyridylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00103
  • 1H NMR (500 MHz, DMSO) d 3.12 (m, 6H), 3.44 (m, 4H), 3.64 (m, 4H), 4.52 (m, 4H), 5.55 (t, 1H), 6.51-6.91 (br, 2H), 7.01 (m, 2H), 7.30-7.40 (m, 5H), 8.01 ((m, 2H)
    • Example 97 Carbamic acid 4-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 1-(3-chloro-pyridin-2-yl)-piperazine as starting materials.
    Figure US20120095007A2-20120419-C00104
  • 1H NMR (500 MHz, DMSO) d 1.78 (m, 5H), 3.80 (m, 3H), 3.52 (m, 3H), 3.41 (m, 3H), 5.02 (br, 2H), 5.50 (t, 1H), 7.10 (m, 1H), 7.41 (m, 5H), 7.91 (m, 1H), 8.31 ((m, 1H)
    • Example 98 Carbamic acid 3-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and 3,4-methylene dioxy benzylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00105
  • 1H NMR (200 MHz, Acetone) d 1.99 (m, 2H), 2.35 (m, 10H), 3.40 (d, 2H), 5.78 (t, 1H), 5.97 (br, 4H), 6.78 (d, 2H), 6.87 (s, 1H), 7.36 (m, 5H)
    • Example 99 Carbamic acid 3-(4-benzoyl-piperazin-1-yl)-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzoyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00106
  • 1H NMR (200 MHz, CDCl3) d 1.9-2.3 (m, 8H), 3.2-3.8 (br, 4H), 4.95 (br, 2H), 5.82 (t, 1H), 7.32-7.39 (m, 10H)
    • Example 100 Carbamic acid 3-(4-benzyl-piperazin-1-yl)-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzyl piperazine as starting materials.
    Figure US20120095007A2-20120419-C00107
  • 1H NMR (200 MHz, Acetone) d 2.07 (m, 2H), 2.41 (m, 10H), 3.53 (s, 2H), 4.90 (br, 2H), 5.70 (t, 1H), 7.31 (m, 10H)
    • Example 101 Carbamic acid (R)-3-[4-(4-methoxy-phenyl)-2,6-dimethyl-piperazin-1-yl]-1-phenyl-propyl ester
  • (R)-3-chloro-1-phenyl-1-propanol (10 mmol) was dissolved in acetonitrile (100 ml), and 2,6-dimethyl-4-methoxy phenylpiperazine (12 mmol) and triethylamine (12 mmol) were added to the resulting mixture. The prepared mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate. The extracted organic phase was washed with an aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under a reduced pressure to obtain a pellet. The prepared pellet (8.2 mmol) was dissolved in tetrahydrofuran (50 mL), and 1,1′-carbonyl dimidazole (16.5 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 1 hour. Excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred for 2. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. Then, the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting yellow pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
    Figure US20120095007A2-20120419-C00108
  • 1H NMR (200 MHz, CDCl3) d 1.05 (dd, 6H), 1.99 (m, 2H), 2.45 (m, 2H), 2.78 (m, 4H), 3.27 (m, 2H), 3.78 (s, 3H), 4.71 (br, 2H), 5.66 (t, 1H), 6.85 (m, 4H), 7.3 (m, 5H)
    • Example 102 (R)-carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl ]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00109
  • 1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
    • Example 103 (R)-carbamic acid 3-[4-(4-chloro-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-chlorophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00110
  • 1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.67 (br, 2H), 5.76 (t, 1H), 6.85 (m, 2H), 7.24 (m, 2H), 7.37 (m, 5H)
    • Example 104 (R)-carbamic acid 3-[4-(4-fluoro-phenyl)-piperazin-1-yl]1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-fluorophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00111
  • 1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
    • Example 105 (R)-carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-hydroxyphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00112
  • 1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.14 (m, 2H), 2.58 (m, 4H), 3.12 (m, 4H), 5.12 (br, 2H), 5.78 (t, 1H), 6.99 (m, 4H), 7.21 (m, 5H)
    • Example 106 (S)-carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester
  • A title compound was prepared in the same manner as in Example 101 except for the use of (S)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00113
  • 1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
    • Example 107 4-{2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-ethyl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one
  • 2′-nitro acetophenone (4.67 mmol) and 4-methoxyphenylpiperazine (5.61 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was adjusted to pH 2 to 3 by adding concentrated hydrochloric acid dropwise. Paraformaldehyde (37.36 mmol) was added to the mixture, and the resulting mixture was refluxed for 24 hours. The resulting reaction mixture were distilled under a reduced pressure, neutralized with 1 normal sodium chloride aqueous solution, diluted with water, and then extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a crude compound. The separated crude compound (3.65 mmol) was dissolved in methanol (30 mL), and cooled to 0° C., and sodium borohydride (NaBH4, 7 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure. Then, the resulting orange pellet was purified with column chromatography (hexane:ethylacetate=1:1). The purified compound (3.1 mmol) was dissolved in methanol, and subject to the hydrogenation reaction at the presence of platinum catalyst to obtain an amino compound with a reduced nitro group. The prepared compound (1.21 mmol) was dissolved in tetrahydrofuran (20 mL), and triethylamine (3 mmol) was added, and phosgene (a 2.4 M toluene solution, 1.21 mmol) was added slowly to the mixture. In this case, a temperature of the reaction product was carefully maintained in a temperature range of no more than 10° C. The reaction product was stirred at a room temperature for 16 hours, diluted with ammonium hydroxide, and then extracted several times with ethyl acetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and re-crystallized from ethyl acetate to prepare a final compound.
    Figure US20120095007A2-20120419-C00114
  • 1H NMR (200 MHz, CDCl3) d 2.07 (m, 4H), 2.61 (m, 4H), 3.12 (m, 4H), 3.78 (s, 3H), 5.58 (t, 1H), 6.85 (m, 5H), 7.16 (m, 1H), 7.22 (m, 3H), 9.14 (s, 1H)
    • Example 108 Carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • Phenyl-1-propenyl-ketone (4.1 mmol) and 4-methoxy phenylpiperazine (4.9 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was stirred at 72° C. for 48 hours. The mixture was distilled under a reduced pressure, diluted with water, and then extracted twice with ethyl acetate. The resulting organic phase was distilled under a reduced pressure, dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and purified with column chromatography (hexane:ethylacetate=4:1) to obtain a crude compound. The prepared crude compound (2.9 mmol) was dissolved in methanol (20 mL), and NaBH4 (3.8 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hour, and concentrated under a reduced pressure, and obtained a yellow pellet. The prepared yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1). The purified compound (2 mmol) was dissolved in tetrahydrofuran (15 mL), and 1,1′-carbodiimidazole (4 mmol) was added to the purified compound. The resulting mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a final compound.
    Figure US20120095007A2-20120419-C00115
  • 1H NMR (200 MHz, CDCl3) d 1.81 (m, 1H), 2.32 (m, 1H), 2.5 (m, 3H), 2.8 (m, 2H), 3.14 (m, 4H), 3.80 (s, 3H), 4.80 (br, 2H), 6.02 (t, 1H), 6.92 (m, 4H), 7.36 (m, 5H)
    • Example 109 Carbamic acid 3-[4-(4-chloro-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-chlorophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00116
  • 1H NMR (200 MHz, CDCl3) d 1.82 (m, 2H), 2.31 (m, 1H), 2.74-2.55 (m, 8H), 3.18 (m, 3H), 4.69 (br, 2H), 5.90 (t, 1H), 6.87 (m, 2H), 7.22 (m, 2H), 7.32 (m, 5H)
    • Example 110 Carbamic acid 3-[4-(4-nitro-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-nitrophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00117
  • 1H NMR (200 MHz, CDCl3) d 1.81 (m, 2H), 1.91 (m, 1H), 2.20-2.90 (m, 8H), 3.45 (m, 3H), 4.75 (br, 2H), 5.92 (t, 1H), 6.84 (m, 2H), 7.35 (m, 5H), 8.13 (m, 2H)
    • Example 111 Carbamic acid 3-[4-(3,4-dimethyl-phenyl)-piperazin-1-yl]1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethylphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00118
  • 1H NMR (200 MHz, CDCl3) d 1.72 (m, 2H), 2.20 (s, 3H), 2.52 (s, 3H), 2.52 (m, 4H), 2.80 (m, 3H), 3.17 (m, 5H), 5.01 (br, 2H), 5.82 (t, 1H), 6.90 (m, 2H), 7.05 (m, 1H), 7.37 (m, 5H)
    • Example 112 Carbamic acid 3-[4-(4-quinoxaline-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2-piperazin-1-yl-quinoxaline as starting materials.
    Figure US20120095007A2-20120419-C00119
  • 1H NMR (200 MHz, CDCl3) d 1.71 (m, 2H), 2.21 (m, 2H), 2.48-2.78 (m, 7H), 3.83 (m, 3H), 4.69 (br, 2H), 5.87 (t, 1H), 7.38 (m, 5H), 7.61 (m, 3H), 7.86 (m, 1H), 8.59 (d, 1H)
    • Example 113 Carbamic acid 3-[4-(3,4-dimethoxy-phenyl)-piperazin-1-yl ]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethoxyphenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00120
  • 1H NMR (200 MHz, CDCl3) d 1.32 (m, 1H), 2.21 (m, 1H), 2.42 (m, 4H), 2.72 (m, 4H), 3.10 (m, 5H), 3.80 (s, 3H), 3.83 (s, 3H), 5.01 (br, 2H), 5.89 (t, 1H), 6.42 (d, 1H), 6.80 (d, 1H), 6.89 (d, 1H), 7.33 (m, 5H)
    • Example 114 Carbamic acid 3-[4-(3,5-dichloro-pyridin-2-yl-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,5-dichloropyridylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00121
  • 1H NMR (200 MHz, CDCl3) d 1.68 (m, 1H) 2.21 (m, 2H), 2.54 (m, 4H), 2.71 (m, 2H), 3.36 (m, 5H), 5.01 (br, 2H), 5.91 (t, 1H), 7.2-7.4 (m, 5H), 7.60 (m, 1H), 8.10 (m, 1H)
    • Example 115 Carbamic acid 3-[4-(3,4-dichloro-phenyl)-piperazin-1-yl]1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dichlorophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00122
  • 1H NMR (200 MHz, CDCl3) d 1.62 (m, 2H), 1.96 (m, 2H), 2.20-2.60 (m, 5H), 2.75 (m, 2H), 3.16 (m, 3H), 4.96 (br, 2H), 5.91 (t, 1H), 6.77 (m, 1H), 7.00 (m, 1H), 7.36 (m, 6H)
    • Example 116 Carbamic acid 3-[4-(2,4-difluoro-phenyl)-piperazin-1-yl]-1-phenyl-butyl ester
  • A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2,4-difluorophenylpiperazine as starting materials.
    Figure US20120095007A2-20120419-C00123
  • 1H NMR (200 MHz, CDCl3) 1.86 (m, 2H), 2.12 (m, 2H), 2.52 (m, 4H), 2.75 (m, 3H), 3.06 (m, 3H), 4.98 (br, 2H), 5.81 (t, 1H), 6.79 (m, 3H), 7.36 (m, 5H)
    • Example 117 Carbamic acid 2-fluoro-1-phenyl-3-(4-phenyl-piperazin-1-yl)-propyl ester
  • 3-chloropropiophenone (14.77 mmol) and phenylpiperazine (17.7 mmol) were dissolved in acetonitrile (50 mL), and triethylamine (17.7 mmol) was added thereto, and the resulting mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate. The extracted organic phase was collected, washed with water and an aqueous saturated sodium chloride solution, dried over magnesium sulfate, and then concentrated under a reduced pressure to obtain a pellet. The prepared pellet (1.75 mmol) was dissolved in tetrahydrofuran (20 mL), and 1.5 mole of a cyclohexanelithium diimide (1.92 mmol) solution was added dropwise while the resulting mixture was maintained to a temperature of −78° C. Then, the resulting mixture was stirred at −78° C. for 10 minutes, and then stirred at 0° C. for 30 minutes. After the resulting mixture was cooled again and maintained to a temperature of −78° C., N-fluorobenzenesulfonimide (2.27 mmol) was added to the mixture, and the resulting mixture was stirred at a room temperature for 2 hours. The resulting reaction mixture was diluted by adding a saturated ammonium chloride solution, and the diluted reaction mixture was extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. In this case, the resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:4) to obtain a crude compound. The prepared crude compound (1.5 mmol) was dissolved in methanol (20 mL), and NaBH4 (3.0 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 1 hour, and concentrated under a reduced pressure to remove off solvents. The resulting pellet was then purified with column chromatography (hexane:ethylacetate=1:2) to obtain a crude compound. The prepared crude compound (1 mmol) was dissolved in tetrahydrofuran (20 mL), and 1,1′-carbodiimidazole (2 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 2 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and then concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:4) to obtain a final compound.
    Figure US20120095007A2-20120419-C00124
  • 1H NMR (200 MHz, CDCl3) d 2.59 (m, 6H), 3.19 (m, 4H), 4.92 (m, 1H, J=48 Hz), 5.52 (br, 2H), 5.92 (m, 1H, J=18 Hz), 6.90 (m, 3H), 7.34 (m, 7H)
  • The compounds as listed above were tested for analgesic effects using the following animal models.
  • 2. Acetic Acid-Induced Writhing Test in Mouse
  • An acetic acid-induced writhing test is one of models for measuring an analgesic effect of drugs. A test material dissolved in a suitable vehicle was orally administered to a male ICR mouse weighing 30 to 35 g at an amount of 10 mg/kg. After 1 hour of the oral administration, 10 mg/ml of an aqueous 0.8% acetic acid solution was intraperitoneally injected into the male ICR mouse to induce the abdominal pain of the male ICR mouse. Right after the administration of acetic acid, the male ICR mouse was put into an empty cage, and the number of writhing behaviors of the mice was counted for 10 minutes. The term “writhing represents a reflex action in which the mouse overtly extends its abdomen by stretching its hind legs due to the abdominal pain. The analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ {[(Writhing number of Vehicle-administered group−Writhing number of Test material-administered group)/(Writhing number of Vehicle-administered group)]×100%} or 50% of Effective amount (ED50 (median effective dose); an amount of test material that is required to suppress 50% of pain behaviors) of Test material. The ED50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED50 value.
  • 3. Formalin Test—Late Phase in Mouse
  • A formalin test is another model for measuring an analgesic effect of drugs. When a formalin solution was subcutaneously administered into the planta surface of a mouse's hindlimb, the mouse shows specific pain behaviors such as immediately holding up and down, flinching and licking a mouse's left foot. These pain behaviors have a biphasic pattern, and therefore they are divided into an early-phase behavior within 10 seconds after the formalin administration; and a late-phase behavior up to 10 to 60 minutes. The medicinal effect observed in the formalin test-late phase means an analgesic effect of the test material in the inflammatory pain model, and also becomes a measure that may predict the medicinal effects in the neuropathic pain model (Vissers K et. al, 2003). A test material was orally administered to a male ICR mouse weighing 30 to 35 g. After 1 hour of the oral administration, 20 μl of a 2.5% formalin solution was subcutaneously injected into the planta surface of a mouse's hindlimb to induce pain. After 20 minutes of the administration of the formalin solution, the time when the mouse shows the pain behaviors (flinching, licking, etc.) was recorded for 15 minutes, and quantified. The analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ {[(Pain response time of Vehicle-administered group−Pain response time of Test material-administered group)/(Pain response time of Vehicle-administered group)]×100%}, or ‘50% of Effective amount (ED50; an amount of a test material that is required to suppress 50% of pain behaviors) of Test material’. The ED50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED50 value.
    TABLE II
    Results on Acetic acid - induced writhing test and Formalin
    test - late phase in mouse
    Suppression ratio of Pain
    response (% at 10 po) or ED50
    (po or ip)
    compound AA Writhing Formal in
    Example 1: carbamic acid ED50 = 6.31 po ED50 = 8.43 po
    1-phenyl-3-(4-phenyl-piperazin-1-yl)-
    propyl ester
    Example 2: carbamic acid ED50 = 2.14 po ED50 = 2.20 po
    1-(4-chloro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 4: carbamic acid 48% 13%
    1-(3-nitro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 5: carbamic acid 62% 51%
    1-(4-tert-butyl-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 6: carbamic acid ED50 = 2.79 po ED50 = 4.45 po
    1-(4-fluoro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 7: carbamic acid 59% 27%
    1-(3-chloro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 8: carbamic acid 43% 38%
    1-(4-methoxy-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 9: carbamic acid 91% ED50 = 2.39 po
    1-(4-nitro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 10: carbamic acid 100% (10 ip) 64%
    3-(4-phenyl-piperazin-1-yl)-1-
    p-tolyl-propyl ester
    Example 11: carbamic acid 48% —
    3-[4-(2,3-dihydro-benzo[1.4]dioxin-
    6-yl)-piperazin-1-yl]-1-phenyl-propyl
    ester
    Example 12: carbamic acid 18% —
    1-phenyl-3-[4-(4-trifluoromethoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 13: carbamic acid 34% —
    3-[4-(2,4-dimethyl-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 16: carbamic acid ED50 = 2.92 ip ED50 = 11.6 po
    1-phenyl-3-[4-(4-nitro-phenyl)-
    piperazin-1-yl]-propyl ester
    Example 17: carbamic acid 19% —
    3-[4-(2,4-dimethoxy-phenyl)-
    piperazin-1-yl]-phenyl-propyl ester
    Example 18: carbamic acid 52% —
    3-[4-(4-chloro-3-trifluoromethyl-
    phenyl)-piperazin-1-yl]-1-
    phenyl-propyl ester
    Example 19: carbamic acid 48% —
    3-[4-(2,6-dimethyl-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 20: carbamic acid ED50 = 3.12 po ED50 = 5.77 po
    3-[4-(4-methoxy-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 21: carbamic acid 88% 61%
    3-[4-(4-fluoro-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 22: carbamic acid 52% (10 ip) −7%
    3-[4-(4-chloro-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 23: carbamic acid 37% —
    3-[4-(2-hydroxy-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 24: carbamic acid ED50 = 0.81 ip —
    1-phenyl-3-(4-m-tolyl-piperazin-1-yl)-
    propyl ester
    Example 25: carbamic acid 86% (10 ip) —
    1-phenyl-3-(4-pyridin-2-yl-piperazin-1-
    yl)-propyl ester
    Example 26: carbamic acid 55% (10 ip) —
    3-[4-(3-methoxy-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 27: carbamic acid ED50 = 7.80 po —
    3-[4-(2-methoxy-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 28: carbamic acid 48% (10 ip) —
    3-[4-(3-chloro-pyridin-2-yl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 29: carbamic acid 99% —
    3-[4-(3,4-dimethyl-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 30: carbamic acid 93% —
    3-(4-benzo[1,3]dioxol-5-yl-
    piperazin-1-yl)-1-phenyl-propyl ester
    Example 31: carbamic acid 85% —
    3-[4-(3,4-dichloro-phenyl)-piperazin-
    1-yl]-1-phenyl-propyl ester
    Example 32: carbamic acid 23% —
    3-[4-(5-chloro-2-methoxy-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 33: carbamic acid 13% —
    3-[4-(3,5-dimethoxy-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 34: carbamic acid 21% —
    1-phenyl-3-(4-pyrimidin-2-yl-
    piperazin-1-yl)-propyl ester
    Example 35: carbamic acid 50% —
    3-[4-(2-nitro-4-trifluoromethyl-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 36: carbamic acid ED50 = 17.5 po —
    3-[4-(3-chloro-phenyl)-piperazin-1-yl]-
    1-phenyl-propyl ester
    Example 37: carbamic acid ED50 = 1.96 ip ED50 = 42.4 po
    1-phenyl-3-(4-o-tolyl-piperazin-1-yl)-
    propyl ester
    Example 38: carbamic acid
    1-phenyl-3-(4-p-tolyl-piperazin-1-yl)-
    propyl ester
    Example 39: carbamic acid 15% (10 ip) —
    1-phenyl-3-[4-(3-trifluoro
    methyl-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 40: carbamic acid ED50 = 1.64 ip —
    1-phenyl-3-[4-(4-trifluoromethyl-
    phenyl)-piperazin-1-yl]-1-propyl ester
    Example 41: carbamic acid ED50 = 0.34 ip ED50 = 33.2 po
    3-[4-(2-fluoro-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 42: carbamic acid 96% (10 ip) —
    3-[4-(3-fluoro-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 43: carbamic acid 25% (10 ip) —
    3-[4-(2-nitro-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 44: carbamic acid 64% —
    3-[4-(4-methoxy-phenyl)-piperazin-
    1-yl]-1-(4-nitro-phenyl)-propyl ester
    Example 45: carbamic acid 62% —
    1-(3-chloro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 46: carbamic acid 42% —
    1-(2-fluoro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 47: carbamic acid 53% —
    1-(4-methoxy-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 48: carbamic acid 93% —
    1-(4-tert-butyl-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 49: carbamic acid 64% —
    3-[4-(4-methoxy-phenyl)-piperazin-
    1-yl]-1-naphthalen-2-yl-propyl ester
    Example 50: carbamic acid 49% —
    1-(2-chloro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 51: carbamic acid 95% —
    3-[4-(4-methoxy-phenyl)-piperazin-
    1-yl]-1-(4-trifluoromethyl-
    phenyl)-propyl ester
    Example 52: carbamic acid 61% —
    1-(3,4-difluoro-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-
    yl]-propyl ester
    Example 53: carbamic acid 57% —
    1-(3-fluoro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 54: carbamic acid 69% —
    1-(3-methoxy-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 55: carbamic acid 16% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-naphthalen-1-yl-propyl ester
    Example 56: carbamic acid 93% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-p-tolyl-propyl ester
    Example 57: carbamic acid 52% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-m-tolyl-propyl ester
    Example 58: carbamic acid 16% —
    1-(2,4-dichloro-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 59: carbamic acid 48% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-o-tolyl-propyl ester
    Example 60: carbamic acid 62% —
    1-(2,4-dimethyl-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 61: carbamic acid 58% —
    1-(3,4-dimethyl-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 62: carbamic acid 62% —
    1-(2,5-dimethyl-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 63: carbamic acid 46% —
    1-(4-chloro-3-trifluoromethyl-phenyl)-
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-propyl ester
    Example 64: carbamic acid 59% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-(2-nitro-phenyl)-propyl ester
    Example 65: carbamic acid 39% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-(3-nitro-phenyl)-propyl ester
    Example 66: carbamic acid 95% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-(4-trifluoromethyl-phenyl)-
    propyl ester
    Example 67: carbamic acid 57% —
    1-benzo1,3]dioxol-5-yl-3-[4-(4-
    methoxy-phenyl)-piperazin-1-
    yl]-propylester
    Example 68: carbamic acid 48% —
    3-[4-(4-methoxy-phenyl)-piperazin-
    1-yl]-1-(3-trifluoromethyl-
    phenyl)-propyl ester)
    Example 69: carbamic acid 57% —
    1-(2-fluoro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 70: carbamic acid 51% —
    1-(3,4-dichloro-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-
    yl]-propyl ester
    Example 71: carbamic acid 61% —
    1-(4-chloro-phenyl)-3-[4-(4-
    methoxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 72: carbamic acid 53% —
    1-(4-chloro-3-trifluoromethyl-phenyl)-
    3-[4-(4-hydroxy-phenyl)-piperazin-
    1-yl]-propyl ester
    Example 73: carbamic acid 55% —
    1-(3,4-dichloro-phenyl)-3-[4-(4-
    hydroxy-phenyl)-piperazin-1-yl]-
    propyl ester
    Example 74: carbamic acid 44% —
    3-[4-(2-ethoxy-phenyl)-piperazin-1-
    yl]-1-(4-fluoro-phenyl)-propyl ester
    Example 75: carbamic acid 14% —
    3-[4-(5-chloro-2-methoxy-phenyl)-
    piperazin-1-yl]-1-(4-fluoro-phenyl)-
    propyl ester
    Example 76: carbamic acid 50% —
    3-[4-(3,4-dichloro-phenyl)-piperazin-1-
    yl]-1-(4-fluoro-phenyl)-propyl ester
    Example 77: carbamic acid ED50 = 12.4 po −18%
    1-(4-fluoro-phenyl)-3-[4-(4-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 78: carbamic acid 34% —
    1-(4-fluoro-phenyl)-3-[4-(2-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 79: carbamic acid 70% −5%
    1-(4-fluoro-phenyl)-3-[4-(4-
    nitro-phenyl)-piperazin-1-yl]-propyl
    ester
    Example 80: carbamic acid 29% —
    1-(4-fluoro-phenyl)-3-(4-o-tolyl-
    piperazin-1-yl)-propyl ester
    Example 81: carbamic acid 52% —
    1-(4-fluoro-phenyl)-3-[4-(4-fluoro-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 82: carbamic acid 55% —
    2-[4-(4-methoxy-phenyl)-piperazin-1-
    ylmethyl]-1,2,3,4-tetrahydro-
    naphthalen-1-yl ester
    Example 85: carbamic acid 58% —
    3-[4-(4-benzyloxyphenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 86: acetic acid ED50 = 7.52 po 34%
    4-[4-(3-carbamoyloxy-3-phenyl-propyl)-
    piperazin-1-yl]-phenyl ester
    Example 87: carbamic acid 58% —
    3-[4-(4-cyclopentyloxy-phenyl)-
    piperazin-1-yl]-1-phenyl-propyl ester
    Example 88: carbamic acid ED50 = 7.24 po 22%
    1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 89: 1-(4-fluorophenyl)-3-(4-(4- 63% —
    (pivaloyloxy)phenyl)piperazin-1-yl)
    propyl carbamate
    Example 90: carbonic acid ED50 = 23.4 po —
    4-{4-[3-carbamoyloxy-3-(4-fluoro-
    phenyl)-propyl]-piperazin-1-
    yl}-phenyl ethyl ester
    Example 91: carbonic acid benzyl ester 45% —
    4-{4-[3-carbamoyloxy-3-(4-fluoro-
    phenyl)-propyl]-piperazin-1-yl}-
    phenyl ester
    Exampic 92: acetic acid ED50 = 0.22 ip —
    4-{4-[3-carbamoyloxy-3-(4-fluoro- ED50 = 5.66 po
    phenyl)-propyl]-piperazin-1-yl}-
    phenyl ester
    Example 93: carbamic acid 47% (10 ip) 30%
    3-{4-[bis-(4-fluoro-phenyl)-methyl]-
    piperazin-1-yl}-1-phenyl-propyl ester
    Example 94: carbamic acid ED50 = 0.25 ip ED50 = 2.79 ip
    1-phenyl-4-(4-phenyl-piperazin-1-yl)- ED50 = 3.61 po
    butyl ester
    Example 95: carbamic acid 100% (10 ip) —
    4-[4-(2-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-butyl ester
    Example 96: carbamic acid 79% (10 ip) —
    1-phenyl-4-(4-pyridin-2-yl-piperazin-1-
    yl)-butyl ester
    Example 97: carbamic acid 100% (10 ip) —
    4-[4-(3-chloro-pyridin-2-yl)-piperazin-
    1-yl]-1-phenyl-butyl ester
    Example 98: carbamic acid −13% (10 ip) —
    3-(4-benzo[1,3]dioxol-5-ylmethyl-
    piperazin-1-yl)-1-phenyl-propyl ester
    Example 99: carbamic acid 44% (10 ip) —
    3-(4-benzoyl-piperazin-1-yl)-1-phenyl-
    propyl ester
    Example 100: carbamic acid 32% (10 ip) —
    3-(4-benzyl-piperazin-1-yl)-1-phenyl-
    propyl ester
    Example 101: carbamic acid 48% —
    (R)-3-[4-(4-methoxy-phenyl)-2,6-
    dimethyl-piperazin-1-yl]-1-phenyl-
    propyl ester
    Example 102: (R)-carbamic acid ED50 = 3.15 po ED50 = 4.77 po
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 105: (R)-carbamic acid ED50 = 6.49 po 20.9%
    3-[4-(4-hydroxy-phenyl)-piperazin-1- @ 10 ip
    yl]-1-phenyl-propyl ester
    Example 106: (S)-carbamic acid ED50 = 1.43 ip ED50 = 12.5 po
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 107: 4-{2-[4-(4-methoxy- 35% —
    phenyl)-piperazin-1-yl]-ethyl}-1,4-
    dihydro-benzo [d] [1,3]oxazin-2-one
    Example 108: carbamic acid 83.5% —
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-butyl ester
    Example 109: carbamic acid 84% —
    3-[4-(4-chloro-phenyl)-piperazin-1-yl]-
    1-phenyl-butyl ester
    Example 110: carbamic acid 17% —
    3-[4-(4-nitro-phenyl)-piperazin-1-yl]-1-
    phenyl-butyl ester
    Example 111: carbamic acid 95% —
    3-[4-(3,4-dimethyl-phenyl)-piperazin-
    1-yl]-1-phenyl-butyl ester
    Example 112: carbamic acid 72% —
    3-[4-(4-quinoxaline-phenyl)-piperazin-
    1-yl]-1-phenyl-butyl ester
    Example 113: carbamic acid 57% —
    3-[4-(3,4-dimethoxy-phenyl)-piperazin-
    1-yl]-1-phenyl-butyl ester
    Example 114: carbamic acid 39% —
    3-[4-(3,5-dichloro-pyridin-2-yl-
    piperazin-1-yl]-1-phenyl-butyl ester
    Example 115: carbamic acid 68% —
    3-[4-(3,4-dichloro-phenyl)-piperazin-1-
    yl]-1-phenyl-butyl ester
    Example 116: carbamic acid 87% —
    3-[4-(2,4-difluoro-phenyl)-
    piperazin-1-yl]-1-phenyl-butyl ester
    Example 117: carbamic acid ED50 = 32.2 po —
    2-fluoro-1-phenyl-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
  • It has been known that the actions of serotonin (5-HT) receptors are closely related to the induction of various psychiatry disorders, for example, depression, anxiety, schizophrenia, phobia, obsession, migraine headache, panic disorder, etc. The serotonin receptor is divided into subtypes including 5-HT1, 5-HT2, 5HT3, 5-HT4, 5-HT6, 5-HT7, etc. In particular, the 5-HT1 receptor is divided into subtypes: 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F etc. From the preclinical electrophysiologic test, it was found that the 5-HT1A receptor of postsynaptic neuron is associated with the anti-depression effect. Also, it was found that stimulation of the 5-HT1A receptor of the postsynaptic increases the anxiety, and activation of the 5-HT1A receptor of presynaptic reduces the anxiety. The 5-HT2A receptor tends to sharply decrease from adolescence to middle age of a normal human, and to slowly decrease after the middle age. A level of the 5-HT2A receptor in an elderly patient suffering from depression is very lower than that of the normal human, and therefore it was found that the deficiency of serotonin in a wide region of brain may be one cause of the depression in the elderly. The above-mentioned compounds were tested for medicinal effects against depression and anxiety through their binding to the 5-HT1A receptor and the 5-HT2A receptor.
  • Binding to 5-HT1A Receptor
  • 10 6-week-old Sprague-Dawley (SD) rats were anesthetized in an ether container for minutes, brains were separated from rats, and cortical regions were then separated from the brains of the rats. The cortical regions of the rats were put into a Tris-HCl buffer solution (50 mM, pH 7.4) and homogenized, and the homogenate was centrifuged twice at 4? at a rotary speed of 50,000 g to obtain a precipitate (membrane protein). The precipitate was put into a buffer solution, and homogenized, which was used later as a protein source. 2 nM [3H]-8-OH-DPAT was used as a radioactive isotope, and 10 uM serotonin was used to remove non-specific bindings. 25 ul of the compound, 100 ul of an aqueous radioactive isotope solution, and 100 ul of the protein source were put together, and kept at 25° C. for 1 hour. The resulting mixture was filtered with a membrane filter in a 96-well harvester when the 96-well plate reaction was completed. The competitivity of the compound to [3H]-8-OH-DPAT was determined by taking the membrane filter and measuring the radioactivity of the membrane filter in a scintillation counter, and an IC50 value was determined by measuring the increasing concentration of the compound. The specific reaction of the compound accounted for 90% or more. The general experiments were carried out according to the method by Middlemiss et al. (1984, Eur. J. Pharmacol.).
  • Binding to 5-HT2A Receptor
  • 10 6-week-old Sprague-Dawley (SD) rats were anesthetized in an ether container for 5 minutes, brains were separated from rats, and cortical regions were then separated from the brains of the rats. The cortical regions of the rats were put into a Tris-HCl buffer solution (50 mM, pH 7.7) and homogenized, and the homogenate was centrifuged twice at 4° C. at a rotary speed of 50,000 g to obtain a precipitate (membrane protein). The precipitate was put into a buffer solution, and homogenized, which was used later as a protein source. 0.5 nM [3H]-Ketanserin was used as a radioactive isotope, and 10 uM serotonin was used to remove non-specific bindings. 25 ul of the compound, 100 ul of an aqueous radioactive isotope solution, and 100 ul of the protein source were put together, and kept at 25° C. for 1 hour. The resulting mixture was filtered with a membrane filter in a 96-well harvester when the 96-well plate reaction was completed. The competitivity of the compound to [3H]-Ketanserin was determined by taking the membrane filter and measuring the radioactivity in a scintillation counter, and an IC50 value was determined by measuring the increasing concentration of the compound. The specific reaction of the compound accounted for 90% or more. The general experiments were carried out according to the method by Leysen et al. (1982, Eur. J. Pharmacol).
    TABLE 2
    Test results on Binding of 5-HT1A and 5-HT2A Receptors
    Suppression (at 1 uM) or
    Concentration (nM) required
    to be 50% suppressed
    Compound 5-HT1A 5-HT2A
    Example 1: carbamic acid IC50 = 434 nM IC50 = 139 nM
    1-phenyl-3-(4-phenyl-piperazin-1-
    yl)-propyl ester
    Example 2: carbamic acid 64.6% 84.6%
    1-(4-chloro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 4: carbamic acid 74.6% 86.4%
    1-(3-nitro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 5: carbamic acid 44.4% 98.8%
    1-(4-tert-butyl-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 6: carbamic acid 65.5% 84.7%
    1-(4-fluoro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 7: carbamic acid 76.4% 93.7%
    1-(3-chloro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 8: carbamic acid 67.7% 82.0%
    1-(4-methoxy-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 9: carbamic acid 81.4% 88.0%
    1-(4-nitro-phenyl)-3-(4-phenyl-
    piperazin-1-yl)-propyl ester
    Example 10: carbamic acid 59.6% 85.6%
    3-(4-phenyl-piperazin-1-yl)-1-p-
    tolyl-propyl ester
    Example 16: carbamic acid IC50 = 6.57 uM IC50 = 2.05 uM
    1-phenyl-3-[4-(4-nitro-phenyl)-
    piperazin-1-yl]-propyl ester
    Example 20: carbamic acid IC50 = 19.8 uM IC50 = 5.85 uM
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 21: carbamic acid IC50 = 1.05 uM IC50 = 64.5 nM
    3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-
    1-phenyl-propyl ester
    Example 22: carbamic acid IC50 = 1.86 uM IC50 = 264 nM
    3-[4-(4-chloro-phenyl)-piperazin-1-yl]-
    1-phenyl-propyl ester
    Example 25: carbamic acid IC50 = 338 nM IC50 = 448 nM
    1-phenyl-3-(4-pyridin-2-yl-piperazin-1-
    yl)-propyl ester
    Example 26: carbamic acid IC50 = 80.8 nM IC50 = 502 nM
    3-[4-(3-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 27: carbamic acid IC50 = 97.6 nM IC50 = 164 nM
    3-[4-(2-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 36: carbamic acid IC50 = 93.8 nM IC50 = 61.5 nM
    3-[4-(3-chloro-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
    Example 39: carbamic acid IC50 = 12.6 nM IC50 = 660 nM
    1-phenyl-3-[4-(3-trifluoromethyl-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 41: carbamic acid IC50 = 160 nM IC50 = 110 nM
    3-[4-(2-fluoro-phenyl)-piperazin-1-yl]-
    1-phenyl-propyl ester
    Example 78: carbamic acid 79.0% 71.5%
    1-(4-fluoro-phenyl)-3-[4-(2-methoxy-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 79: carbamic acid 29.6% 29.6%
    1-(4-fluoro-phenyl)-3-[4-(4-nitro-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 80: carbamic acid 75.3% 76.8%
    1-(4-fluoro-phenyl)-3-(4-o-tolyl-
    piperazin-1-yl)-propyl ester
    Example 81: carbamic acid 60.9% 93.9%
    1-(4-fluoro-phenyl)-3-[4-(4-fluoro-
    phenyl)-piperazin-1-yl]-propyl ester
    Example 93: carbamic acid IC50 = >10 uM IC50 = 940 nM
    3-{4-[bis-(4-fluoro-phenyl)-methyl]-
    piperazin-1-yl}-1-phenyl-propyl ester
    Example 94: carbamic acid IC50 = 89.8 nM IC50 = 514 nM
    1-phenyl-4-(4-phenyl-piperazin-1-yl)-
    butyl ester
    Example 95: carbamic acid IC50 = 5.82 nM IC50 = 1.15 uM
    4-[4-(2-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-butyl ester
    Example 96: carbamic acid IC50 = 20.4 nM IC50 = 3.14 uM
    1-phenyl-4-(4-pyridin-2-yl-piperazin-1-
    yl)-butyl ester
    Example 97: carbamic acid IC50 = 181 nM IC50 = 519 nM
    4-[4-(3-chloro-pyridin-2-yl)-piperazin-
    1-yl]-1-phenyl-butyl ester
    Example 102: (R)-carbamic acid IC50 = 4.31 uM IC50 = 2.78 uM
    3-[4-(4-methoxy-phenyl)-piperazin-1-
    yl]-1-phenyl-propyl ester
  • For the use in treating various diseases such as a wide range of pains (including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression), anxiety and depression, the compound of the present invention is administered to patient, alone or in combinations with pharmaceutically available carriers. An exact dose of the administered compound may be determined according to the conditions of patients, the severity of patient status and the activity of the compound. Under the specific circumstances, the optimum dose of the administered compound should essentially be determined in a clinical manner, but be present within the scope of the present invention.
  • For the use of the compound according to the present invention, the compound is preferably administered orally since the compound is easily absorbed orally, but the present invention is not particularly limited thereto. For the oral administration, the compound represented by Formula 1 is preferably used in combinations with a pharmaceutical carrier. A dose ratio of the carrier to the inventive compound is limited to allow the compound to take an effect on patients, and may be widely varied, depending on whether the composition is filled into a capsule, or formulated into a tablet. In the case of the tablet, edible and pharmaceutical carriers or mixtures thereof may be used herein. Examples of the suitable carriers includes, but are not particularly limited to, lactose, dibasic calcium phosphate and/or corn starch, and mixtures thereof, etc. Other pharmaceutically available compounds may be further added, including a lubricant such as magnesium stearate.

Claims (14)

1. A carbamoyloxy arylalkan arylpiperazine derivative compound having racemic or enantiomeric characteristics, represented by Formula 1, and pharmaceutically acceptable salts or hydrates thereof:
Figure US20120095007A2-20120419-C00125
wherein, - - - may selectively form a cyclic ring;
R1 and R2 are hydrogen, or R1 or R2 may be taken together with the phenyl group to form a bicyclic ring;
X1 represents at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having 1 to 6 carbon atoms, halogen such as F, Cl and Br, straight or branched alkoxy having 1 to 6 carbon atoms, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
Z is hydrogen, fluorine, or carbon which may be taken together with the phenyl group to form a bicyclic ring;
Ar is selected from the group consisting of phenyl, pyridine, and pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having 1 to 6 carbon atoms, hydroxy, halogen, straight or branched alkoxy having 1 to 6 carbon atoms, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline;
Y1 and Y2 are each independently hydrogen or methyl;
Y3 is hydrogen, phenyl, or carbonyl;
Y4 is hydrogen, or methyl;
n is integer of 1 or 2; and
m is integer of 0 or 1.
2. A compound in accordance with claim 1, wherein said compound comprises carbamic acid 1-(4-chloro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester.
3. A compound in accordance with claim 1, wherein said, compound comprises carbamic acid 1-(4-fluoro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester.
4. A compound in accordance with claim 1, wherein said, compound comprises carbamic acid 1-(4-nitro-phenyl)-3-(4-phenyl-piperazin-1-yl)-propyl ester.
5. A compound in accordance with claim 1, wherein said, compound comprises carbamic acid 1-phenyl-3-[4-(4-nitro-phenyl)-piperazin-1-yl]-propyl ester.
6. A compound in accordance with claim 1, wherein said, compound comprises carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester.
7. A compound in accordance with claim 1, wherein said, compound comprises carbamic acid 3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester.
8. A compound in accordance with claim 1, wherein said, compound comprises R)-carbamic acid 3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester.
9. A pharmaceutical composition for treating anxiety or depression, comprising an effective amount of a compound as defined in claim 1.
10. A pharmaceutical composition for treating pain, comprising an effective amount of a compound as defined in claim 1.
11. A pharmaceutical composition in accordance with claim 10, wherein the pain is selected from the group consisting of acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain and migraine headache.
12. A method for treating pain, anxiety or depression in mammals by administering to the mammals in need of treatment thereof an effective amount of a compound as defined in claim 1.
13. A method in accordance with claim 12, wherein the effective amount of said compound is administered in a unit dose comprising from 10 to 500 mg of the total active components.
14. A method in accordance with claim 13, wherein the effective amount of said compound is administered in a daily dose of from 10 to 7000 mg.
US12/600,283 2007-05-14 2008-04-30 Carbamoyloxy arylalkan arylpiperazine analgesics Active 2031-11-24 US8815852B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2007-0046708 2007-05-14
KR20070046708 2007-05-14
PCT/KR2008/002466 WO2008140197A1 (en) 2007-05-14 2008-04-30 Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Publications (3)

Publication Number Publication Date
US20100160331A1 US20100160331A1 (en) 2010-06-24
US20120095007A2 true US20120095007A2 (en) 2012-04-19
US8815852B2 US8815852B2 (en) 2014-08-26

Family

ID=40002366

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/600,291 Active 2029-05-14 US8541409B2 (en) 2007-05-14 2008-04-30 Carbamoyloxy arylalkanoyl arylpiperazine analgesics
US12/600,283 Active 2031-11-24 US8815852B2 (en) 2007-05-14 2008-04-30 Carbamoyloxy arylalkan arylpiperazine analgesics
US14/028,284 Active US8901116B2 (en) 2007-05-14 2013-09-16 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/600,291 Active 2029-05-14 US8541409B2 (en) 2007-05-14 2008-04-30 Carbamoyloxy arylalkanoyl arylpiperazine analgesics

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/028,284 Active US8901116B2 (en) 2007-05-14 2013-09-16 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound

Country Status (18)

Country Link
US (3) US8541409B2 (en)
EP (2) EP2155736B1 (en)
JP (2) JP5387917B2 (en)
KR (2) KR101468553B1 (en)
CN (2) CN101679400B (en)
AT (1) ATE538104T1 (en)
AU (1) AU2008251259B2 (en)
BR (1) BRPI0811245B1 (en)
CA (2) CA2686926C (en)
DK (1) DK2155736T3 (en)
ES (2) ES2379848T3 (en)
HK (1) HK1141019A1 (en)
MX (1) MX2009012331A (en)
PL (1) PL2155736T3 (en)
PT (1) PT2155736E (en)
RU (1) RU2460731C2 (en)
WO (2) WO2008140197A1 (en)
ZA (1) ZA200907956B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195963A1 (en) * 2007-05-14 2011-08-11 Byong Sung Kwak Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101642B2 (en) 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
JP5527668B2 (en) * 2008-06-05 2014-06-18 エスケー バイオファーマスティカルズ カンパニー リミテッド 3-substituted propanamine compounds
US8835436B2 (en) 2009-07-10 2014-09-16 Green Cross Corporation Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
KR101810975B1 (en) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 Pharmaceutical compositions comprising carbamoyloxy arylalkanoyl arylpiperazine compound
ES2584702T3 (en) 2012-06-20 2016-09-28 Novartis Ag Complement path modulators and uses thereof
KR20210062029A (en) * 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 Use of carbamate compounds for the prevention, alleviation or treatment of diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
US20130131081A1 (en) * 2010-07-08 2013-05-23 Sk Biopharmaceuticals Co., Ltd. Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135756A (en) 1964-06-02 Table ii
US3002976A (en) 1959-10-12 1961-10-03 Paul A J Janssen 1-(2-thienyl)-omega-(4-arylpiperazine)alkanols
DE2325633A1 (en) 1973-05-21 1974-12-12 Boehringer Sohn Ingelheim PIPERAZINE DERIVATIVES
NL8202636A (en) 1982-06-29 1984-01-16 Gist Brocades Nv PIPERAZINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS.
JPS6175A (en) 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl) piperazine derivative
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
KR0173310B1 (en) 1989-04-22 1999-02-01 폴 에이 리쳐 Piperazine derivatives, their preparation method and pharmaceutical composition comprising thereof
US5364849A (en) 1989-04-22 1994-11-15 John Wyeth & Brother, Limited 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
AU6120298A (en) * 1997-03-07 1998-09-22 Takeda Chemical Industries Ltd. 2-peperazinone-1-acetic acid derivatives and their use
ES2128266B1 (en) 1997-07-08 2000-01-16 Vita Invest Sa THIOPHENE AND BENZOTIOFEN DERIVATIVE COMPOUNDS AND RELEVANT USE AND COMPOSITION.
DE19934433A1 (en) * 1999-07-22 2001-01-25 Merck Patent Gmbh New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
ITMI20021327A1 (en) 2002-06-14 2003-12-15 Recordati Chem Pharm NEW OSSIALCHILPIPERAZINE
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
JP4769082B2 (en) 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use
PE20060426A1 (en) * 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
RU2009104750A (en) 2006-08-17 2010-09-27 Ф. Хоффманн-Ля Рош Аг (Ch) ARILPIPERASIN DERIVATIVES AND THEIR APPLICATION
CA2686926C (en) 2007-05-14 2016-01-05 Sk Holdings Co., Ltd. Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
US20130131081A1 (en) * 2010-07-08 2013-05-23 Sk Biopharmaceuticals Co., Ltd. Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195963A1 (en) * 2007-05-14 2011-08-11 Byong Sung Kwak Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
US8541409B2 (en) * 2007-05-14 2013-09-24 Sk Biopharmaceuticals Co., Ltd. Carbamoyloxy arylalkanoyl arylpiperazine analgesics
US8901116B2 (en) 2007-05-14 2014-12-02 Sk Biopharmaceuticals Co., Ltd. Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound

Also Published As

Publication number Publication date
EP2150550B1 (en) 2013-02-27
EP2155736B1 (en) 2011-12-21
JP2010526870A (en) 2010-08-05
KR20080100765A (en) 2008-11-19
KR101468553B1 (en) 2014-12-09
RU2009146132A (en) 2011-06-20
PT2155736E (en) 2012-03-28
US8815852B2 (en) 2014-08-26
US20140088095A1 (en) 2014-03-27
EP2155736A4 (en) 2010-11-10
KR20080100766A (en) 2008-11-19
ZA200907956B (en) 2011-01-26
US20110195963A1 (en) 2011-08-11
DK2155736T3 (en) 2012-03-12
EP2155736A1 (en) 2010-02-24
CA2686926A1 (en) 2008-11-20
CA2686547C (en) 2015-12-08
BRPI0811245B1 (en) 2021-05-25
CA2686547A1 (en) 2008-11-20
CN101679399B (en) 2013-11-06
US8541409B2 (en) 2013-09-24
CN101679399A (en) 2010-03-24
KR101451799B1 (en) 2014-10-16
BRPI0811245A2 (en) 2014-11-04
MX2009012331A (en) 2010-02-10
ES2379848T3 (en) 2012-05-04
JP5387917B2 (en) 2014-01-15
ATE538104T1 (en) 2012-01-15
US20100160331A1 (en) 2010-06-24
CA2686926C (en) 2016-01-05
PL2155736T3 (en) 2012-09-28
HK1141019A1 (en) 2010-10-29
WO2008140197A1 (en) 2008-11-20
AU2008251259B2 (en) 2013-02-14
JP2010526871A (en) 2010-08-05
US8901116B2 (en) 2014-12-02
RU2460731C2 (en) 2012-09-10
AU2008251259A1 (en) 2008-11-20
WO2008140198A1 (en) 2008-11-20
CN101679400B (en) 2013-04-17
JP5605569B2 (en) 2014-10-15
CN101679400A (en) 2010-03-24
ES2402173T3 (en) 2013-04-29
EP2150550A1 (en) 2010-02-10
EP2150550A4 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
US8815852B2 (en) Carbamoyloxy arylalkan arylpiperazine analgesics
US9278943B2 (en) Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
TWI357901B (en) Substituted morpholine and thiomorpholine derivati
CA2195427A1 (en) Novel aryl piperazine-derived piperazide derivatives, methods for their preparation, their use as drugs and pharmaceutical compositions comprising same
EA005975B1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
SI20269A (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
US5710152A (en) Benzoazine derivative or salt thereof and pharmaceutical compostion comprising the same
FR2531085A1 (en) NOVEL XANTHINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
DK159435B (en) METHOD OF ANALOGUE FOR PREPARING 2-HYDROXY-5- (1-HYDROXY-2-PIPERAZINYLETHYL) BENZOIC ACID DERIVATIVES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT
RU2007386C1 (en) Aryloxyalkenylene derivatives of amines or theirs pharmaceutically acceptable salts showing antidepressant activity
KR101819472B1 (en) Novel 1,4-substituted piperazine or piperidine compounds and pharmaceutical composition comprising the same
JPH02286650A (en) Novel spasmolytic compound for bronchospasm and its production
US6890955B2 (en) Aryloxypropanolamine derivatives, method of preparation and applications thereof
JP2009504648A (en) Piperazine derivatives
KR101936054B1 (en) Anti-inflammatory 6-phenoxypyrimidine derivatives, process for their preparation and pharmaceutical composition containing them

Legal Events

Date Code Title Description
AS Assignment

Owner name: SK HOLDINGS CO., LTD.,KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KI HO;YI, HAN JU;CHO, HYEON;AND OTHERS;SIGNING DATES FROM 20091111 TO 20091112;REEL/FRAME:023521/0709

Owner name: SK HOLDINGS CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KI HO;YI, HAN JU;CHO, HYEON;AND OTHERS;SIGNING DATES FROM 20091111 TO 20091112;REEL/FRAME:023521/0709

AS Assignment

Owner name: SK HOLDINGS CO. LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IM, DAE JOONG;REEL/FRAME:025851/0993

Effective date: 20110209

AS Assignment

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KOREA, REPUBLIC O

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SK HOLDINGS CO., LTD.;REEL/FRAME:027558/0316

Effective date: 20111004

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8